Improved IgG degrading enzymes and methods of use thereof
By developing IdeS protein variants with improved thermal stability and cleavage efficiency, the problem of the difficulty in degrading IgG antibodies in existing technologies has been solved, enabling effective treatment of autoimmune disorders and improving the success rate of transplantation and gene therapy.
Patent Information
- Application Number
- CN202380028367.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-16
- Filing Date
- 2023-03-14
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies are unable to effectively degrade and inactivate pathogenic IgG antibodies in the human body, especially in autoimmune disorders and transplantation or gene therapy, which affects treatment efficacy.
IdeS protein variants with improved thermal stability and cleavage efficiency were developed to reduce the concentration of IgG antibodies by degrading, digesting, or inactivating them to treat related diseases.
It effectively reduces the concentration of IgG antibodies in the body fluids of subjects, alleviates disease symptoms, and improves the success rate of transplantation and the effectiveness of gene therapy.
Smart Images

Figure CN118946364A_ABST
Abstract
Description
Reference to a sequence listing
[0001] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy created on February 16, 2023 is named PC072839_SequenceListing_ST26.xml and is 100,559 bytes in size. Background Art
[0002] The immunoglobulin G degrading enzyme of Streptococcus pyogenes (IdeS) is a naturally occurring cysteine protease expressed by the pathogenic bacterium Streptococcus pyogenes that shows specificity for its target sequence found in human IgG, among several other species. IdeS is able to cleave IgG below the hinge region, resulting in the generation of F(ab')2 and Fc / 2 fragments. IdeS is able to cleave IgG in human plasma and can reduce total IgG levels in humans shortly after its administration.
[0003] Certain disorders and diseases in humans are mediated by IgG antibodies, especially autoimmune disorders such as type 1 diabetes and multiple sclerosis, which cause indescribable pain. In addition, the presence of IgG antibodies may hinder the successful administration of established life-saving therapies (e.g., organ transplants) and recently developed treatments (e.g., gene therapy using recombinant viral vectors). Various methods have been tried to mitigate the harmful effects of such pathogenic IgG antibodies in patients with autoimmune disorders and candidates for transplantation and gene therapy, but the efficacy is incomplete.
[0004] Therefore, there is a need in the art for compositions and methods that can degrade, digest and inactivate pathogenic IgG antibodies in subjects, particularly human subjects with autoimmune disorders or human subjects who are candidates for transplantation or gene therapy. And, related to this need, there is also a need for IdeS protein variants with improved potency and / or stability. Summary of the invention
[0005] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by Example (E) below. E1. An isolated cysteine protease that specifically cleaves immunoglobulin G (IgG) antibody molecules. E2. The cysteine protease of E1, wherein the protease has greater potency or thermostability relative to wild-type IdeS. E3. The cysteine protease of E2, wherein the cysteine protease has a T as determined using differential scanning calorimetry.起始 ℃, 3.2℃, 3.3℃, 3.4℃, 3.5℃, 3.6℃, 3.7℃, 3.8℃, 3.9℃, or 4.0℃ greater than the wild-type IdeS protein. E4. The cysteine protease of E2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. 起始 value of at least or about 44.0, 44.1, 44.2, 44.3, 44.4, 44.5, 44.6, 44.7, 44.8, 44.9, 45.0, 45.1, 45.2, 45.3, 45.4, 45.5, 45.6, 45.7, 45.8, 45.9, 46.0, 46.1, 46.2, 46.3, 46.4, 46.5, 46.6, 46.7, 46.8, 46.9, 9, 47.0, 47.1, 47.2, 47.3, 47.4, 47.5, 47.6, 47.7, 47.8, 47.9, 48.0, 48.1, 48.2, 48.3, 48.4, 48.5, 48.6, 48.7, 48.8, 48.9, 49.0, 49.1, 49.2, 49.3, 49.4, 49.5, 49.6, 49.7, 49.8, 49.9 or 50.0°C. E5. The cysteine protease of E2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. M ℃, 3.2℃, 3.3℃, 3.4℃, 3.5℃, 3.6℃, 3.7℃, 3.8℃, 3.9℃, or 4.0℃ greater than the wild-type IdeS protein. E6. The cysteine protease of E2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. Mvalue, which value is at least or about 51.0°C, 51.1°C, 51.2°C, 51.3°C, 51.4°C, 51.5°C, 51.6°C, 51.7°C, 51.8°C, 51.9°C, 52.0°C, 52.1°C, 52.2°C, 52.3°C, 52.4°C, 52.5°C, 52.6°C, 52.7°C, 52.8°C, 52.9°C, 53.0°C, 53.1°C, 53.2°C, 53.3°C, 53.4°C, 53.5°C, 53.6°C, 53.7°C, 53.8°C, 53.9°C ℃, 54.0℃, 54.1℃, 54.2℃, 54.3℃, 54.4℃, 54.5℃, 54.6℃, 54.7℃, 54.8℃, 54.9℃, 55.0℃, 55.1℃, 55.2℃, 55.3℃, 55.4℃, 55.5℃, 55.6℃, 55.7℃, 55.8℃, 55.9℃, 56.0℃, 56.1℃, 56.2℃, 56.3℃, 56.4℃, 56.5℃, 56.6℃, 56.7℃, 56.8℃, 56.9℃ or 57.0℃. E7. The cysteine protease of E2, wherein the cysteine protease has an IgG cleavage potency as determined using ELISA and expressed as an IC50 value that is at least or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4 or 2.5 nM less than wild-type IdeS. The cysteine protease of E2, wherein the cysteine protease has an IgG cleavage potency as determined using ELISA and expressed as an IC50 value of at most 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8 or 3.7 nM. E8. The cysteine protease of E2, wherein the amino acid sequence of the cysteine protease comprises, consists essentially of, or consists of amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71. E9. The cysteine protease as described in E9, wherein the amino acid sequence of the cysteine protease comprises, consists essentially of, or consists of the amino acid sequence of any one of SEQ ID NOs: 72-82. E10. A pharmaceutical composition comprising the cysteine protease according to any one of embodiments E1 to E10 and a pharmaceutically acceptable carrier. E11. A method for treating a subject in need of treatment or prevention of a disease or disorder characterized by an excess of IgG antibodies, the method comprising administering to the subject an amount of a cysteine protease as described in E10 effective to reduce the concentration of IgG antibodies in the subject's body fluids. E12. The method of E12, wherein the body fluid is blood, plasma or serum. E13. The method of E12, wherein the cysteine protease acts by degrading, digesting or inactivating the IgG antibody. E14. The method of E12, wherein the disease or disorder is an autoimmune disease or disorder, and wherein administration of the cysteine protease is effective to treat or prevent the autoimmune disease or disorder. E15. The method of E15, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject. E16. A method as described in E15, wherein the treatment effectively reduces the concentration of total IgG in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. E17. A method as described in E15, wherein the treatment effectively reduces the concentration of total IgG in the subject's body fluids to no more than about 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 grams per liter. E18. A method for treating a sensitized subject in need of a tissue or organ transplant, the method comprising administering to the subject an amount of a cysteine protease as described in E10, which is effective to reduce the concentration of anti-HLA antibodies in the subject's body fluids, thereby sufficiently preventing antibody-mediated rejection of the tissue or organ after transplantation. E19. The method of E19, wherein the body fluid is blood, plasma or serum. E20. The method of E19, wherein the cysteine protease acts by degrading, digesting or inactivating the anti-HLA antibody. E21. The method of E19, wherein the organ is kidney, liver, heart, pancreas, lung or intestine. E22. The method of E19, wherein the subject exhibits a calculated population reactive antibody assay score of at least or about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60%. E23. The method of E19, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject. E24. A method as described in E19, wherein the treatment effectively reduces the concentration of anti-HLA antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. E25. The method of E19, wherein the treatment effectively reduces the concentration of total IgG in the subject's body fluids to no more than about 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 g / L. E26. A method as described in E19, wherein the treatment is effective to reduce the calculated population reactive antibody assay score of the subject's serum by at least or about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%. E27. A method as described in E19, wherein the treatment is effective to reduce the calculated population reactive antibody assay score of the subject's serum to no more than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%. E28. The method of E19, wherein the subject subsequently undergoes a tissue or organ transplant and the time period between administration of the cysteine protease and the subsequent transplant is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 hours. E29. A method for treating a subject in need of therapy with a gene therapy vector, the method comprising administering to the subject an amount of a cysteine protease as described in E10, the amount effective to reduce the concentration of IgG antibodies specific for components of the gene therapy vector in the subject's body fluids. E30. The method as described in E30, wherein the body fluid is blood, plasma or serum. E31. The method of E30, wherein the cysteine protease acts by degrading, digesting or inactivating the IgG antibody. E32. The method of E30, wherein the IgG antibody is a neutralizing antibody. E33. The method of E30, wherein the gene therapy vector is a recombinant viral vector. E34. The method of E32, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector. E35. The method of E33, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:5 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000. E36. The method of E33, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg body weight of the subject. E37. A method as described in E33, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. E38. A method as described in E33, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.1. E39. The method of E33, wherein the subject has not received gene therapy treatment. E40. The method of E40, wherein the subject is subsequently treated with the gene therapy vector. E41. The method of E41, wherein the gene therapy vector is a recombinant viral vector. E42. The method of E42, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector. E43. The method of E41, wherein the time period between administration of the cysteine protease and subsequent gene therapy is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 52, 54, 55, 56, 58, 60, 62, 64, 65, 66, 68, 70, 72, 74, 75, 76, 78, 80, 84, 85, 90, 95, 96, 100, 108, 110, 120, 125, 130, 132, 135, 140, 144, 145, 150, 155, 156, 160, 165 or 168 hours or 8, 9, 10, 11, 12, 13 or 14 days. E44. The method of E41, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:5 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000. E45. The method of E41, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg body weight of the subject. E46. A method as described in E41, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. E47. A method as described in E41, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.1. E48. The method of E33, wherein the subject has been previously treated at least once with the same type of gene therapy vector as the subject in need of therapy. E49. The method of E49, wherein the subject is subsequently treated with the gene therapy vector. E50. The method of E50, wherein the gene therapy vector is a recombinant viral vector. E51. The method of E51, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector. E52. The method of E50, wherein the time period between administration of the cysteine protease and subsequent gene therapy is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 52, 54, 55, 56, 58, 60, 62, 64, 65, 66, 68, 70, 72, 74, 75, 76, 78, 80, 84, 85, 90, 95, 96, 100, 108, 110, 120, 125, 130, 132, 135, 140, 144, 145, 150, 155, 156, 160, 165 or 168 hours or 8, 9, 10, 11, 12, 13 or 14 days. E53. The method of E50, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:5 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000. E54. The method of E50, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg body weight of the subject. E55. A method as described in E50, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. E56. A method as described in E50, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.1. E57. The method of any one of embodiments E12 to E57, wherein the subject is a human subject. E58. The method of any one of embodiments E12 to E58, wherein the cysteine protease is administered parenterally. E59. The method of E59, wherein the cysteine protease is administered intravenously or intraarterially. E60. The method of any one of embodiments E12, E19 or E30, wherein the step of administering the cysteine protease to said subject is repeated at least once. E61. A kit comprising a container having disposed therein a pharmaceutical composition comprising a cysteine protease, and a label having instructions for performing the method of any one of embodiments E12 to E61. E62. A polynucleotide encoding the cysteine protease of any one of embodiments E1 to E10. E63. An expression vector comprising the polynucleotide described in E63. E64. A host cell comprising the expression vector as described in E64. E65. The host cell of E65, wherein the host cell is a bacterial host cell. E66. A method for preparing a cysteine protease, the method comprising incubating the host cell according to E66 under conditions sufficient to express the cysteine protease, and purifying the cysteine protease produced thereby. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A-1J Depicted is an alignment of the amino acid sequences of wild-type IdeS and IdeS variant proteins generated by protein engineering based on the published IdeS crystal structure. In the variant sequences, the highlighted residues differ from those in the wild-type sequence. Figure 2 Depicted is a bar graph summarizing stability data for certain IdeS variants compared to wild-type IdeS (GBT-NCC-0005). Figure 3A Depicted are Coomassie-stained polyacrylamide gels illustrating protein fragments generated by digestion of IgG protein with wild-type IdeS and certain IdeS variants. Figure 3B Depicted are Coomassie-stained polyacrylamide gels illustrating protein fragments generated by digestion of IgM protein with wild-type IdeS and certain IdeS variants. Figure 4 A schematic diagram of the MSD assay format is depicted. Figure 5 Depicted is a graph summarizing the amount of intact IgG (% of baseline) in rabbits treated with wild-type IdeS (WT) versus IdeS variant (Var). Figure 6 A schematic diagram of the MSD LBA assay format is depicted. Figure 7 Depicted is a graph summarizing the average PK of IdeS variants (triangles) and wild-type IdeS (squares). DETAILED DESCRIPTION General techniques
[0006] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are fully explained in the literature, e.g., Molecular Cloning: A Laboratory Manual, 2nd ed. (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (JE Cellis, ed., 1998) Academic Press; Animal Cell Culture (RI Freshney, ed., 1987); Introuction to Cell and Tissue Culture (JP Thayer and PE Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Notebook (JP Cellis, ed., 1998) Academic Press; Procedures [Cell and Tissue Culture: Laboratory Procedures] (A. Doyle, JB Griffiths, and DG Newell, eds., 1993-1998) J. Wiley and Sons; Methods in Enzymology [Enzymology Methods] (Academic Press, Inc.); Handbook of Experimental Immunology [Experimental Immunology Handbook] (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells [Gene Transfer Vectors for Mammalian Cells] (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology [Current Protocols in Molecular Biology] (FMAusubel et al., eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligogan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practical approach (D. Catty., eds., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 1994); Press [Oxford University Press], 2000); Using antibodies: a laboratory manual [Using antibodies: a laboratory manual] (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press [Cold Spring Harbor Laboratory Press], 1999); The Antibodies [Antibodies] (M. Zanetti and JD Capra, eds., Harwood Academic Publishers [Harwood Academic Publishers], 1995). definition
[0007] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the present specification (including definitions) shall prevail. Unless the context otherwise requires, singular terms shall include plural forms, and plural terms shall include singular forms. Any examples following the term "eg or for example" are not intended to be exhaustive or restrictive. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.
[0008] Unless otherwise indicated, the following terms shall be understood to have the following meanings: The term "isolated molecule" refers to a molecule (wherein the molecule is, for example, a protein, polynucleotide, or antibody) that, by virtue of its origin or source of derivation, is: (1) unassociated with naturally associated components that accompany it in its native state, (2) substantially free of other molecules from the same source (e.g., species, cells expressing it, libraries, etc.), (3) expressed by cells from a different species, or (4) not present in nature. Thus, a chemically synthesized molecule or a molecule expressed in a cell system different from its natural origin system will be "isolated" from its naturally associated components. A molecule may also be rendered substantially free of naturally associated components by separation using purification techniques well known in the art. Molecular purity or homogeneity may be determined by a variety of means well known in the art. For example, the purity of a polypeptide sample may be determined using polyacrylamide gel electrophoresis and staining the gel using techniques well known in the art to visualize the polypeptide. For some purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.
[0009] As used herein, "variant", "variant protein" or "protein variant" refers to a protein that differs from a parent protein due to at least one amino acid modification. A protein variant may refer to the protein itself, a composition comprising the protein, or an amino acid sequence encoding the protein. Preferably, the protein variant has at least one amino acid modification compared to the parent protein, for example, from about one to about ten amino acid modifications compared to the parent, and preferably from about one to about five amino acid modifications. The protein variant sequence herein will preferably have at least about 80% homology with the parent protein sequence, and most preferably at least about 90% homology, more preferably at least about 95% homology. A variant protein may refer to the variant protein itself, a composition comprising the protein variant, or an amino acid sequence encoding the protein variant. Therefore, as used herein, "IdeS variant" means a protein that differs from wild-type IdeS due to at least one amino acid modification. Variants may comprise non-natural amino acids. Examples include US 6586207; WO 98 / 48032; WO 03 / 073238; US2004-0214988 A1; WO 05 / 35727A2; WO 05 / 74524A2; JW Chin et al., (2002), Journal of the American Chemical Society [American Chemical Society Journal] 124:9026-9027; JW Chin, and PGSchultz, (2002), ChemBioChem [Chemical Biochemistry] 11:1135-1137; JW Chin et al., (2002), PICAS United States of America [USA PICAS] 99:11020-11024; and L. Wang, and PGSchultz, (2002), Chem. [Chemistry] 1-10.
[0010] As used herein, "protein" herein means at least two covalently attached amino acids, which include proteins, polypeptides, oligopeptides and peptides. The peptidyl group can include naturally occurring amino acids and peptide bonds, or synthetic peptide mimetic structures, i.e., "analogs", such as peptoids (see Simon et al., PNAS USA [Proceedings of the National Academy of Sciences of the United States of America] 89(20):9367(1992)). Amino acids can be naturally occurring or non-naturally occurring; as will be understood by those skilled in the art. For example, homophenylalanine, citrulline and norleucine are considered amino acids for the purposes of the present invention, and amino acids in both D- and L- (R or S) configurations can be used. Variants of the invention may include modifications including unnatural amino acids incorporated using techniques such as those developed by Schultz and colleagues, including but not limited to the methods described in Cropp and Shultz, 2004, Trends Genet. 20(12):625-30, Anderson et al., 2004, Proc Natl Acad Sci USA 101(2):7566-71, Zhang et al., 2003, 303(5656):371-3, and Chin et al., 2003, Science 301(5635):964-7. In addition, the polypeptides may include synthetic derivatization of one or more side chains or termini, glycosylation, pegylation, ring permutations, cyclizations, linkers to other molecules, fusions to proteins or protein domains, and addition of peptide tags or labels.
[0011] As used herein, "wild type" or "WT" refers to an amino acid sequence or nucleotide sequence found in nature, including allelic variations. A wild type protein has an amino acid sequence or nucleotide sequence that has not been intentionally modified.
[0012] "Individual" or "subject" is a mammal, more preferably a human. Mammals also include, but are not limited to, farm animals (e.g., cows, pigs, horses, chickens, etc.), competitive animals, pets, primates, horses, dogs, cats, mice and rats.
[0013] As used herein, an "effective dose" or "effective amount" of a drug, compound, or pharmaceutical composition is an amount sufficient to achieve any one or more beneficial or desired results. In more specific aspects, an effective amount prevents, alleviates, or improves the symptoms of a disease, and / or prolongs the survival of a treated subject. For preventive use, a beneficial or desired result includes eliminating or reducing the risk of a disease (including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes presented during disease development), reducing the severity of the disease, or delaying the onset of the disease. For therapeutic use, a beneficial or desired result includes, for example, the following clinical results: alleviating one or more symptoms of the disease, reducing the dose of other drugs required for treating the disease, enhancing the effect of another drug, and / or delaying the progression of the patient's disease. An effective dose may be administered in one or more administrations. For purposes of the present invention, an effective dose of a drug, compound, or pharmaceutical composition is an amount sufficient to directly or indirectly complete a preventive or therapeutic treatment. As understood in a clinical context, an effective dose of a drug, compound, or pharmaceutical composition may or may not be used in conjunction with another drug, compound, or pharmaceutical composition. Thus, in the context of administration of one or more therapeutic agents, an "effective dose" may be considered, and a single agent may be considered to be administered in an effective amount if the desired result can be or has been achieved when used in combination with one or more other agents.
[0014] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein and refer to all forms of nucleic acids, oligonucleotides, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Nucleic acids include genomic DNA, cDNA and antisense DNA, as well as spliced or unspliced mRNA, rRNA tRNA and inhibitory DNA or RNA (RNAi, e.g., small or short hairpin (sh) RNA, micro RNA (miRNA), small or short interfering (si) RNA, trans-splicing RNA or antisense RNA).
[0015] "Heterologous" nucleic acid sequence refers to a polynucleotide inserted into a plasmid or vector for the purpose of vector-mediated transfer / delivery of the polynucleotide into a cell. A heterologous nucleic acid sequence is different from a viral nucleic acid, that is, it is non-natural relative to a viral nucleic acid. Once transferred / delivered into a cell, the heterologous nucleic acid sequence contained in the vector can be expressed (e.g., transcribed and translated (if appropriate)). Alternatively, it is not necessary to express the heterologous polynucleotides transferred / delivered in the cell contained in the vector. Although the term "heterologous" is not always used herein to refer to nucleic acid sequences and polynucleotides, even in the absence of the modifier "heterologous", referring to a nucleic acid sequence or polynucleotide is intended to include heterologous nucleic acid sequences and polynucleotides (although the modifier is omitted).
[0016] As used herein, "transgenic" conveniently refers to a nucleic acid that is intended to or has been introduced into a cell or organism. A transgenic includes any nucleic acid, such as a heterologous polynucleotide sequence or a heterologous nucleic acid encoding a protein or peptide. The terms transgenic and heterologous nucleic acid / polynucleotide sequence are used interchangeably herein.
[0017] "Host cell" includes a single cell or cell culture that can be or has been a recipient of a vector for incorporating a polynucleotide insert. Host cells include the progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. Host cells include cells transfected in vivo with one or more polynucleotides of the invention.
[0018] As used herein, "vector" means a construct that is capable of delivering and preferably expressing one or more target genes or sequences in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells (such as production cells).
[0019] The term "recombinant" as a modifier of viral vectors (e.g., recombinant AAV (rAAV) vectors) and sequences (e.g., recombinant polynucleotides and polypeptides) means that the composition has been manipulated in a manner that does not normally occur in nature. A specific example of a recombinant AAV vector would be the insertion of a nucleic acid (heterologous polynucleotide) that is not normally present in the wild-type AAV genome into the viral genome. An example is the cloning of a nucleic acid (e.g., a gene) encoding a therapeutic protein or polynucleotide sequence into a vector with or without the 5', 3' and / or intron regions that are normally associated with the gene within the AAV genome. Although the term "recombinant" is not always used herein with respect to AAV vectors and sequences (e.g., polynucleotides), recombinant forms comprising AAV vectors, polynucleotides, etc. are expressly included despite any such omissions.
[0020] For example, a "rAAV vector" is a wild-type genome derived from AAV by removing all or part of the wild-type AAV genome using molecular methods and replacing it with a non-natural (heterologous) nucleic acid (e.g., a nucleic acid encoding a therapeutic protein or polynucleotide sequence). Typically, for rAAV vectors, one or two inverted terminal repeat (ITR) sequences of the AAV genome are retained. The difference between rAAV and the AAV genome is that all or part of the AAV genome has been replaced by a non-natural sequence relative to the AAV genomic nucleic acid (e.g., a heterologous nucleic acid encoding a therapeutic protein or polynucleotide sequence). Therefore, the incorporation of non-natural (heterologous) sequences defines AAV as a "recombinant" AAV vector, which can be referred to as a "rAAV vector."
[0021] Recombinant AAV vector sequences can be packaged and are referred to herein as "particles" for subsequent infection (transduction) of cells ex vivo, in vitro or in vivo. When the recombinant vector sequences are encapsidated or packaged into AAV particles, the particles may also be referred to as "rAAV", "rAAV particles" and / or "rAAV virions". Such rAAV, rAAV particles and rAAV virions include proteins that encapsidate or package the vector genome. In some embodiments, such included proteins are capsid proteins.
[0022] "Vector genome" (which may be abbreviated as "vg") refers to the portion of the recombinant plasmid sequence that is ultimately packaged or encapsidated to form rAAV particles. In the case where the recombinant plasmid is used to construct or manufacture a recombinant AAV vector, the AAV vector genome does not include a "plasmid" portion that does not correspond to the vector genome sequence of the recombinant plasmid. This non-vector genome portion of the recombinant plasmid is called the "plasmid backbone," which is very important for the cloning and amplification of the plasmid (a process required for propagation and recombinant AAV vector production), but it itself is not packaged or encapsidated into rAAV particles. Therefore, "vector genome" refers to the nucleic acid that is packaged or encapsidated by rAAV.
[0023] The term "PEG" refers to polyethylene glycol, a linear water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEG is classified by its molecular weight; for example, PEG 2000 has an average molecular weight of about 2,000 Daltons, and PEG 5000 has an average molecular weight of about 5,000 Daltons. PEG is commercially available from Sigma Chemical Co. and other companies, and includes, for example, the following functional PEGs: monomethoxy polyethylene glycol (MePEG-OH), monomethoxy polyethylene glycol-succinate (MePEG-S), monomethoxy polyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxy polyethylene glycol-amine (MePEG-NH2), monomethoxy polyethylene glycol-tresylate (MePEG-TRES) and monomethoxy polyethylene glycol-imidazolyl-carbonyl (MePEG-IM). In some embodiments, PEG can be a polyethylene glycol with a mean molecular weight of about 550 to about 10,000 daltons, and is optionally substituted with an alkyl, alkoxy, acyl or aryl group. In some embodiments, PEG can be substituted with a methyl group at the terminal hydroxyl position. In some embodiments, PEG can have a mean molecular weight of about 750 to about 5,000 daltons, or about 1,000 to about 5,000 daltons, or about 1,500 to about 3,000 daltons, or about 2,000 daltons or about 750 daltons. PEG can be optionally substituted with an alkyl, alkoxy, acyl or aryl group. In some embodiments, the terminal hydroxyl group can be substituted with a methoxy or methyl group.
[0024] As used herein, the term "serotype" with respect to AAV vectors means a capsid that is serologically different from other AAV serotypes. Serological differences are determined by the lack of cross-reactivity between one AAV antibody and another AAV antibody. Cross-reactivity differences are usually due to differences in capsid protein sequences / antigenic determinants (e.g., due to differences in VP1, VP2, and / or VP3 sequences of AAV serotypes). Due to the homology of capsid protein sequences, an AAV antibody can cross-react with one or more other AAV serotypes. Under the traditional definition, serotype means that the neutralizing activity of the target virus has been tested for all existing and characterized serotypes with specific sera, and no antibodies to neutralize the target virus have been found. With the discovery of more naturally occurring virus isolates and / or the generation of capsid mutants, it may or may not have serological differences with any currently existing serotype. Therefore, if a new virus (e.g., AAV) has no serological differences, the new virus (e.g., AAV) will be a subgroup or variant of the corresponding serotype. In many cases, mutant viruses with capsid sequence modifications have not been serologically tested for neutralizing activity to determine whether they belong to another serotype according to the traditional definition of serotype. Therefore, for convenience and to avoid repetition, the term "serotype" refers broadly to serologically different viruses (e.g., AAV) as well as serologically non-different viruses (e.g., AAV) that may belong to a subgroup or variant of a given serotype.
[0025] As used herein, the term "effector function" with respect to an antibody means the normal functional attributes of an antibody. Non-limiting examples of antibody functional attributes include, for example, binding to an antigen; activation of the complement cascade (called complement-dependent cytotoxicity); binding to Fc receptors on effector cells (e.g., macrophages, monocytes, natural killer cells, and eosinophils) to participate in antibody-dependent cellular cytotoxicity (ADCC); and as a signal for immune cells (e.g., phagocytes and dendritic cells) to ingest bound antigens / pathogens. Therefore, the reduction or inhibition of antibody effector functions may refer to any one or more of the aforementioned non-limiting functional attributes. Effector function assays are known in the art and are described, for example, in WO2016012285.
[0026] "Fc receptor" refers to any Fc receptor. Specific non-limiting examples of Fc receptors include Fcγ immunoglobulin receptors (FcyR) present on cells. In humans, FcyR refers to one, some or all of the Fc receptor family comprising FcyRI (CD64), FcyRIIA (CD32A), FcyRIIB (CD32B), FcyRIIIA (CD16a) and FcyRIIIB (CD 16b). FcyR includes naturally occurring polymorphisms of FcyRI (CD64), FcyRIIA (CD32A), FcyRIIB (CD32B), FcyRIIIA (CD16a) and FcyRIIIB (CD16b).
[0027] Reference herein to "about" a value or parameter includes (and describes) embodiments involving that value or parameter itself. For example, description referring to "about X" includes description of "X." Numerical ranges are inclusive of the numbers defining the range.
[0028] It should be understood that regardless of the situation in which an embodiment is described herein with the language "comprising", additional similar embodiments described with the terms "consisting of" and / or "consisting essentially of" are also provided. Throughout this specification and claims, the word "comprise" or variations such as "comprises" or "comprising" should be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
[0029] When aspects or embodiments of the invention are described in terms of Markush groups or other alternative groupings, the invention encompasses not only the entire group listed as a whole, but also each member of the group individually and all possible subgroups of the main group, as well as the absence of one or more group members from the main group. The invention also contemplates the explicit exclusion of one or more of any group members from the claimed invention.
[0030] All patents, patent applications, publications, and other references, GenBank references, and ATCC references cited herein are incorporated by reference in their entirety. In the event of a conflict, the present specification, including definitions, will control.
[0031] All features disclosed herein can be combined in any combination. Each feature disclosed in this specification can be replaced by an alternative feature for the same, equivalent or similar purpose. Therefore, unless otherwise explicitly stated, the disclosed features are examples of a class of equivalent or similar features.
[0032] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a nucleic acid" includes a plurality of such nucleic acids, reference to a "vector" includes a plurality of such vectors, and reference to a "virus" or "particle" includes a plurality of such viruses / particles.
[0033] As used herein, the term "about" refers to a value within 10% of the underlying parameter. For example, "about 1:10" means 1.1:10.1 or 0.9:9.9, and about 5 hours means 4.5 hours or 5.5 hours, etc. The term "about" preceding a series of values modifies each value by 10%.
[0034] Unless the context clearly indicates otherwise, all numerical values or numerical ranges include integers within such ranges and integers within fractions or ranges of these values. Thus, for illustration, reference to a 95% or greater reduction includes 95%, 96%, 97%, 98%, 99%, 100%, etc., as well as 95.1%, 95.2%, 95.3%, 95.4%, 95.5%, etc., 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, etc. Thus, also for illustration, reference to a numerical range (e.g., "1-4") includes 2, 3, and 1.1, 1.2, 1.3, 1.4, etc. For example, "1 to 4 weeks" includes 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days.
[0035] In addition, reference to numerical ranges, such as "0.01 to 10" includes 0.011, 0.012, 0.013, etc., as well as 9.5, 9.6, 9.7, 9.8, 9.9, etc. For example, a dose of about "0.01 mg / kg to about 10 mg / kg" of a subject's body weight includes 0.011 mg / kg, 0.012 mg / kg, 0.013 mg / kg, 0.014 mg / kg, 0.015 mg / kg, etc., as well as 9.5 mg / kg, 9.6 mg / kg, 9.7 mg / kg, 9.8 mg / kg, 9.9 mg / kg, etc.
[0036] Mentioning integers that are more than (greater than) or less than includes any number that is greater than or less than the reference number, respectively. Thus, for example, mentioning more than 2 includes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc. For example, administering a recombinant viral vector, an IdeS variant "twice or more times" includes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more times. In addition, reference to a numerical range, such as "1 to 90" includes 1.1, 1.2, 1.3, 1.4, 1.5, etc., and 81, 82, 83, 84, 85, etc. For example, "between about 1 minute and about 90 days" includes 1.1 minutes, 1.2 minutes, 1.3 minutes, 1.4 minutes, 1.5 minutes, etc., and one day, 2 days, 3 days, 4 days, 5 days ... 81 days, 82 days, 83 days, 84 days, 85 days, etc.
[0037] Exemplary methods and materials are described herein, but methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. The materials, methods, and examples are illustrative only and not intended to be limiting. IdeS protein variants
[0038] Provided herein are IdeS variants having improved potency and / or stability compared to wild-type IdeS. IdeS is a protein secreted by Streptococcus pyogenes bacteria in its mature form that specifically cleaves human immunoglobulin G (IgG, including its subclasses IgG1, IgG2, IgG3 and IgG4) at its hinge region, but cannot cleave other classes of human immunoglobulins. The amino acid sequence of the naturally occurring IdeS precursor corresponding to protein RefSeq WP_010922160.1 is provided in Table 1 as SEQ ID NO: 1. The protein includes a 29 amino acid long secretion signal peptide (its sequence is provided as SEQ ID NO: 83) and a 310 amino acid long mature polypeptide (its sequence is provided as SEQ ID NO: 84). Additional detailed information on the structure of IdeS can be found, for example, in: von Pawel-Rammingen U, Johansson BP, L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002 Apr 2;21(7):1607-15. doi:10.1093 / emboj / 21.7.1607; Wenig K, et al. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc Natl Acad Sci US A. 2004 Dec 14;101(50):17371-6. doi:10.1073 / pnas.0407965101.
[0039] Based on a rational protein design approach, the present disclosure surprisingly provides certain substitution variants of wild-type IdeS that have higher thermal stability and / or are more effective in the ability to cleave IgG molecules than the wild-type IdeS protein sequence from which they are derived. The names and amino acid sequences of the novel IdeS variants aligned with the reference sequence of the wild-type IdeS protein (RefSeq WP_010922160.1) are disclosed in Figure 1A-1J The wild-type IdeS is illustrated in its precursor form (SEQ ID NO: 1), which includes the naturally occurring secretion signal peptide (SEQ ID NO: 83) at the amino terminus of the mature polypeptide (SEQ ID NO: 84), while the IdeS variant instead begins with the dipeptide Met-Gly and ends with a His tag (SEQ ID NO: 85) that is not present in the wild-type, thereby facilitating small-scale purification. The amino acid differences between the variant and wild-type IdeS are highlighted. Figure 1A-1J The amino acid sequences of the wild-type IdeS and named variants depicted in are further identified by the SEQ ID NOs shown in Table 1 below and other amino acid sequences disclosed herein. Figure 1A-1JThe variants depicted in have different amino and carboxyl termini, but these differences should be considered exemplary rather than limiting. Thus, for example, any variant may not begin with Met-Gly, but with a naturally occurring IdeS secretion signal peptide or some other amino acid sequence at its amino terminus. In addition, any variant may not end with a His tag as described, but with no tag similar to the wild type, or with a different tag or some other amino acid sequence at its carboxyl terminus. Thus, for example, in some embodiments, the variants of the present disclosure may include amino acid numbers 1 to 312 of any one of SEQ ID NOs 2 to 71, or may include amino acid numbers 2 to 312 of any one of SEQ ID NOs 2 to 71, or may include amino acid numbers 3 to 312 of any one of SEQ ID NOs 3 to 71, or any other range of amino acids contained by SEQ ID NOs 2 to 71, or a subsequence thereof. Table 1
[0040] In some embodiments, the amino acid sequence of the IdeS variant protein of the present disclosure comprises, consists of, or consists essentially of the amino acid sequence of a mature wild-type IdeS protein (SEQ ID NO: 84), wherein one or more amino acids are substituted by a different amino acid, and / or wherein one or more amino acids are inserted or deleted, and / or one or more amino acids are added to its amino terminus, and / or one or more amino acids are added to its carboxyl terminus.
[0041] In some embodiments, the amino acid sequence of the IdeS variant protein of the present disclosure comprises, consists of, or consists essentially of: (a) amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71; or (b) a fragment of (a) having Ig endopeptidase activity; or (c) a variant of (a) having at least 50% identity with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71 and having Ig endopeptidase activity; or (d) a variant of (a) having at least 50% identity with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71; A variant of (b) that has at least 50% identity to the corresponding portion of amino acid number 3-312 of any one of NO: 3-71 and has Ig endopeptidase activity.
[0042] In some embodiments, the IdeS variant protein has at least about 60% or more identity (e.g., 60%-70%, 70%-80%, 80%-90%, or 90%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 70% or more identity (e.g., 70%-80%, 80%-90%, or 90%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 80% or more identity (e.g., 80%-90% or 90%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 90% or more identity (e.g., 90%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 95% or more identity (e.g., 95%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 96% or more identity (e.g., 96%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity.In some embodiments, the IdeS variant protein has at least about 97% or more identity (e.g., 97%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 98% or more identity (e.g., 98%-100% identity) with amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity. In some embodiments, the IdeS variant protein has at least about 99% or higher identity (e.g., 99%-100% identity) to amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71, or a fragment thereof having Ig endopeptidase activity.
[0043] In some embodiments, the amino acid sequence of the IdeS variant protein disclosed herein comprises amino acid numbers 1-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NO: 3-71. In some embodiments, the amino acid sequence of the IdeS variant protein disclosed herein consists essentially of amino acid numbers 1-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NO: 3-71. In some embodiments, the amino acid sequence of the IdeS variant protein disclosed herein consists of amino acid numbers 1-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NO: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NO: 3-71.
[0044] In some embodiments, the IdeS variant proteins of the present disclosure comprise, consist of, or consist essentially of an amino acid sequence corresponding to a mature wild-type IdeS protein (SEQ ID NO: 84), because they lack a secretory signal peptide sequence located at the amino terminus of the protein or any other type of foreign peptide sequence located at the amino terminus or carboxyl terminus of such a protein. Non-limiting examples of such embodiments include IdeS variant proteins whose amino acid sequences are provided in SEQ ID NOs: 76, 79, and 82. Additional examples include IdeS protein variants comprising, consisting of, or consisting essentially of amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71.
[0045] In some embodiments, the IdeS variant protein of the present disclosure includes a prokaryotic secretion signal peptide sequence located at the amino terminus of the protein, which promotes the export of the IdeS protein from the bacterial cell after its expression. Such a signal peptide sequence can be a naturally occurring signal peptide sequence of IdeS as provided in SEQ ID NO:83, or a signal peptide sequence of another secretory protein from Streptococcus pyogenes. Therefore, for example, in some embodiments, the IdeS protein variants provided in SEQ ID NO:76, 79 and 82 can each further include SEQ ID NO:83 amino acid sequence at the amino terminus of each such protein. Additional examples include IdeS protein variants including SEQ ID NO:3-71 amino acid numbering 3-312 of any one, each of which further includes SEQ ID NO:83 amino acid sequence at the amino terminus of each such protein. In some other embodiments, the IdeS protein variants of the present disclosure can include a signal peptide from a secretory protein of a bacterial species different from Streptococcus pyogenes (e.g., Escherichia coli (E.coli)) or another species.Additional information about bacterial signal peptides can be found, for example, in Freudl, R. Signal peptides for recombinant protein secretion in bacterial expression systems. Microb Cell Fact 17, 52 (2018). doi: 10.1186 / s12934-018-0901-3; and Kaushik S, He H and Dalbey RE (2022) Bacterial Signal Peptides-Navigating the Journey of Proteins. Front. Physiol. 13: 933153. doi: 10.3389 / fphys.2022.933153; Green ER, Mecsas J. Bacterial Secretion Systems: An Overview. Microbiol Spectr. 2016 Feb;4(1):10.1128 / microbiolspec.VMBF-0012-2015.doi:10.1128 / microbiolspec.VMBF-0012-2015; and Kleiner-Grote GRM, Risse JM, Friehs K. Secretion of recombinant proteins from E. coli. Eng Life Sci. 2018 Apr 14;18(8):532-550.doi:10.1002 / elsc.201700200.
[0046] In some embodiments, for example, where the IdeS variant protein is intended to be expressed in eukaryotic cells, the IdeS variant protein of the present disclosure may comprise a eukaryotic secretion signal peptide sequence corresponding to the cell type in which the variant protein will be expressed. Examples of eukaryotic cells in which the IdeS variant protein can be expressed include yeast cells, plant cells, insect cells, or mammalian cells, among other types.
[0047] In some embodiments, the IdeS variant protein of the present disclosure comprises a short peptide sequence starting with methionine at the amino terminus of the protein, which is encoded by a DNA or RNA sequence sufficient to support the translation of the IdeS variant, but does not necessarily target the expressed protein to be secreted from the cell in which it is expressed. For example, in some embodiments, the IdeS variant protein (or wild-type IdeS) may start with a dipeptide sequence Met-Gly (or MG represented by a single letter code), followed by a mature protein amino acid sequence. In such embodiments, when the IdeS variant protein is not translated with a secretion signal peptide sequence (e.g., when such a protein starts with MG or some other translatable sequence), the protein may be collected in the cell when expressed, and may be released by lysing the cell and then purifying the released protein using methods familiar to ordinary technicians. Therefore, for example, in some embodiments, the IdeS protein variants provided in SEQ ID NOs: 76, 79, and 82 may each further include a dipeptide amino acid sequence Met-Gly (MG) at the amino terminus of each such protein. Additional examples include IdeS protein variants provided in SEQ ID NOs: 2-71, each of which begins with Met-Gly (MG), and in some other embodiments, each of which can be provided without the last nine amino acids present at the corresponding carboxyl termini of SEQ ID NOs: 2-71, corresponding to the His tag of SEQ ID NO: 85. Such embodiments can also be described as IdeS protein variants comprising, consisting of, or consisting essentially of amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71.
[0048] In some embodiments, the amino terminal methionine (M) can be removed during expression or subsequent purification, such as by the action of endogenous aminopeptidases or other mechanisms, so that the main species of the IdeS variant protein lacks methionine (Met, M) at its amino terminus. In contrast, what is present at the amino terminus is the subsequent amino acid immediately after the methionine before the methionine is removed. Thus, for example, in some embodiments, the IdeS protein variants provided in SEQ ID NOs: 76, 79, 82, and 84 can each further comprise a single amino acid Gly (G) at the amino terminus of each such protein. Additional examples include IdeS protein variants comprising amino acid numbering 3-312 of any one of SEQ ID NOs: 2-71, each of which further comprises a single amino acid Gly (G) at the amino terminus of each such protein. Such embodiments can also be described as comprising, consisting of, or essentially consisting of an IdeS protein variant comprising amino acid numbering 2-312 of any one of SEQ ID NOs: 2-71. Still further examples include the IdeS protein variants provided in SEQ ID NOs: 73, 75, 78 and 81, each of which begins with Gly (G).
[0049] In some embodiments, the IdeS protein variants disclosed herein comprise a short sequence of amino acids located at the amino or carboxyl terminus of the protein, which confers some desired functions, such as affinity capture using an antibody metal ion resin. Commonly used peptide and protein tags include those known as CBP, FLAG, GST, HA, HBH, MBP, Myc, poly-His, S-tags, SUMO, TAP, TRX, and V5, and others are also possible. Such tags may also be provided with a protease cleavage site to allow post-translational removal of the tag when desired, non-limiting examples include those known as TEV, thrombin, and PreScission sites, and others are also possible. Tags and other functional peptide and protein moieties that can be fused to the IdeS protein variants of the present disclosure are described in Kimple ME, Brill AL, Pasker RL. Overview of affinity tags for protein purification. Curr Protoc Protein Sci. 2013 Sep 24;73:9.9.1-9.9.23. doi:10.1002 / 0471140864.ps0909s73.
[0050] The modification of polypeptides is a routine practice in the art and need not be described in detail herein. Examples of modified polypeptides include polypeptides with conservative substitutions of amino acid residues, with one or more deletions or additions of amino acids (which do not significantly deleteriously change the functional activity or mature (enhance) the affinity of the polypeptide to its ligand), or using chemical analogs.
[0051] Amino acid sequence insertions include amino-terminal and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include IdeS proteins with N-terminal methionyl residues or IdeS proteins fused to epitope tags. Other insertion variants of the IdeS protein include fusions to the N-terminus or C-terminus of the IdeS protein of an enzyme or polypeptide that increases the half-life of the IdeS protein in the blood circulation.
[0052] Substitution variants remove at least one amino acid residue in the IdeS protein and insert a different residue in its place. Conservative substitutions are shown under the heading "Conservative Substitutions" in Table 2. If such substitutions result in a change in biological activity, more substantial changes, designated "Exemplary Substitutions" in Table 2, or as described further below with reference to amino acid classes, may be introduced and the products screened. Table 2
[0053] Substantial modification of the biological properties of the IdeS protein is accomplished by selecting substitutions that differ significantly in their effects on maintaining: (a) the structure of the polypeptide backbone in the region of the substitution, e.g. sheet or helical conformation; (b) charge or hydrophobicity of the molecule at the target site; or (c) side chain bulk. Naturally occurring residues are grouped based on common side chain properties: (1) Non-polar: norleucine, Met, Ala, Val, Leu, Ile; (2) Polarity: uncharged: Cys, Ser, Thr, Asn, Gln; (3) Acidic (negatively charged): Asp, Glu; (4) Basic (positively charged): Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe, His.
[0054] Non-conservative substitutions are made by exchanging a member of one of these classes for another class.
[0055] The IdeS variant of interest can be sequenced and the polynucleotide sequence can then be cloned into a vector for expression or propagation. The sequence encoding the IdeS variant of interest can be maintained in a vector in a host cell, which can then be expanded and frozen for future use.
[0056] In some embodiments, the IdeS variants disclosed herein have higher thermal stability compared to wild-type IdeS. In some embodiments, improved thermal stability is desirable because it can improve manufacturability, formulations, long-term storage, delivery to patients, and efficacy. Many methods for quantitative protein stability are known in the art, and can be used to measure the thermal stability of IdeS variant proteins compared to wild-type IdeS, examples include circular dichroism (CD), dynamic and static light scattering (DLS and SLS), size exclusion chromatography with multi-angle light scattering (SEC-MALS), Fourier transform infrared spectroscopy (FTIR), analytical ultrafiltration (AUC), size exclusion chromatography (SEC), differential scanning fluorescence (DSF), intrinsic fluorescence (IF) and differential scanning calorimetry (DSC).
[0057] In some embodiments, the thermal stability of IdeS variants is quantified using DSC, which generates two values that can be used to conveniently express thermal stability. Tstart is the temperature at which the pure protein begins to denature, and TM is the thermal transition temperature at which 50% of the protein is in its native conformation and 50% is denatured.
[0058] In some embodiments, the IdeS variants disclosed herein have a Tstart value that is at least or about 0.1°C, 0.2°C, 0.3°C, 0.4°C, 0.5°C, 0.6°C, 0.7°C, 0.8°C, 0.9°C, 1.0°C, 1.1°C, 1.2°C, 1.3°C, 1.4°C, 1.5°C, 1.6°C, 1.7°C, 1.8°C, 1.9°C, 2°C greater than the wild-type IdeS protein. .0°C, 2.1°C, 2.2°C, 2.3°C, 2.4°C, 2.5°C, 2.6°C, 2.7°C, 2.8°C, 2.9°C, 3.0°C, 3.1°C, 3.2°C, 3.3°C, 3.4°C, 3.5°C, 3.6°C, 3.7°C, 3.8°C, 3.9°C or 4.0°C or higher, or any value between or within a range covering any of the values specifically recited above. In some embodiments, the IdeS variants of the present disclosure have a Tstart value of at least or about 44.0°C, 44.1°C, 44.2°C, 44.3°C, 44.4°C, 44.5°C, 44.6°C, 44.7°C, 44.8°C, 44.9°C, 45.0°C, 45.1°C, 45.2°C, 45.3°C, 45.4°C, 45.5°C, 45.6°C, 45.7°C, 45.8°C, 45.9°C, 46.0°C, 46.1°C, 46.2°C, 46.3°C, 46.4°C, 46.5°C, 46.6°C, 46.7°C, 46.8°C, 46.9°C, 47.0°C , 47.1°C, 47.2°C, 47.3°C, 47.4°C, 47.5°C, 47.6°C, 47.7°C, 47.8°C, 47.9°C, 48.0°C, 48.1°C, 48.2°C, 48.3°C, 48.4°C, 48.5°C, 48.6°C, 48.7°C, 48.8°C, 48.9°C, 49.0°C, 49.1°C, 49.2°C, 49.3°C, 49.4°C, 49.5°C, 49.6°C, 49.7°C, 49.8°C, 49.9°C or 50.0°C or more, or any value between or ranges covering any of the values specifically recited above.
[0059] In some embodiments, the IdeS variants disclosed herein have a TM value that is at least or about 0.1°C, 0.2°C, 0.3°C, 0.4°C, 0.5°C, 0.6°C, 0.7°C, 0.8°C, 0.9°C, 1.0°C, 1.1°C, 1.2°C, 1.3°C, 1.4°C, 1.5°C, 1.6°C, 1.7°C, 1.8°C, 1.9°C, 2°C greater than the wild-type IdeS protein. .0°C, 2.1°C, 2.2°C, 2.3°C, 2.4°C, 2.5°C, 2.6°C, 2.7°C, 2.8°C, 2.9°C, 3.0°C, 3.1°C, 3.2°C, 3.3°C, 3.4°C, 3.5°C, 3.6°C, 3.7°C, 3.8°C, 3.9°C or 4.0°C or higher, or any value between or within a range covering any of the values specifically recited above. In some embodiments, the IdeS variants of the present disclosure have a TM value of at least or about 51.0°C, 51.1°C, 51.2°C, 51.3°C, 51.4°C, 51.5°C, 51.6°C, 51.7°C, 51.8°C, 51.9°C, 52.0°C, 52.1°C, 52.2°C, 52.3°C, 52.4°C, 52.5°C, 52.6°C, 52.7°C, 52.8°C, 52.9°C, 53.0°C, 53.1°C, 53.2°C, 53.3°C, 53.4°C, 53.5°C, 53.6°C, 53.7°C, 53.8°C, 53.9°C, 54.0°C, ℃, 54.1 ℃, 54.2 ℃, 54.3 ℃, 54.4 ℃, 54.5 ℃, 54.6 ℃, 54.7 ℃, 54.8 ℃, 54.9 ℃, 55.0 ℃, 55.1 ℃, 55.2 ℃, 55.3 ℃, 55.4 ℃, 55.5 ℃, 55.6 ℃, 55.7 ℃, 55.8 ℃, 55.9 ℃, 56.0 ℃, 56.1 ℃, 56.2 ℃, 56.3 ℃, 56.4 ℃, 56.5 ℃, 56.6 ℃, 56.7 ℃, 56.8 ℃, 56.9 ℃ or 57.0 ℃ or more, or any value between or ranges covering any of the values specifically recited above.
[0060] In some embodiments, the IdeS variants of the present disclosure are more potent than wild-type IdeS. In some embodiments, improved potency is desirable because it allows the same amount of target IgG to be cleaved with a lower mass, concentration, or dose of the IdeS variant compared to wild-type IdeS. Several methods for quantifying the enzymatic potency of IdeS have been described and can be used to measure the potency of IdeS variant proteins compared to wild-type IdeS, for example, ELISA-based methods, visualization of IdeS digestion products of IgG, or mass spectrometry methods, such as those described in Hess, JL, et al., Immunoglobulin cleavage by the streptococcal cysteine protease IdeS can be detected using protein G capture and mass spectrometry, J. Microbiol. Meths., 70(2): 284-291 (2007) (doi.org / 10.1016 / j.mimet.2007.04.017).
[0061] In some embodiments, the efficacy of the IdeS variants disclosed herein can be measured using an ELISA-based sandwich assay. In one version of the assay, human IgG is fixed to an ELISA plate by a capture antibody (e.g., mouse anti-human) specific for human IgG F(ab) regions. The IdeS protein (variant or wild type) is then added to the wells of the plate at varying concentrations and incubated for a predetermined time, which acts to cut the human IgG below the hinge in a sequential process, producing a single cut IgG (scIgG), and then producing a F(ab')2 fragment and two Fc monomers. Vindebro, R, et al., Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization, FEBS Letters 587(12):1818-1822(2013)(doi.org / 10.1016 / j.febslet.2013.04.039). The amount of intact human IgG relative to partially or completely cut IgG can then be measured using a detection antibody specific for the dimeric human IgG Fc domain. The results can be expressed as IC50 values, where lower numbers indicate greater effectiveness.
[0062] In some embodiments, the IdeS variants of the present disclosure have a human IgG cleavage potency as determined using ELISA and expressed as an IC50 value that is at least or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5 nM or less, or an IC50 value between or covering any of the specifically recited values above, as compared to the IC50 value of wild-type IdeS in the same type of assay. In some embodiments, the IdeS variants of the present disclosure have a human IgG cleavage potency as determined using ELISA and expressed as an IC50 value of at most 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8 or 3.7 nM or less, or an IC50 value between or covering any of the values specifically recited above. Methods for producing IdeS protein
[0063] Variant IdeS proteins disclosed herein can be produced using any technique known in the art for producing recombinant proteins. In some embodiments, the coding sequence of the IdeS protein variant can be cloned into an expression vector, introduced into a suitable host cell, and then the sequence is transcribed and translated into protein. The coding sequence can be optimized for the host cell type in which it is expected to be expressed. The IdeS variant protein expressed by the host cell can then be purified using techniques known in the art for purifying recombinant proteins.
[0064] In some embodiments, the expression vector is a bacterial expression vector, which comprises a promoter (e.g., lac, PL or T7 promoter) and a terminator (e.g., T7 terminator) for initiating and terminating transcription of a protein coding sequence, respectively, and other functional elements (e.g., a multiple cloning site into which the coding sequence can be conveniently inserted, a ribosome binding site that increases translation efficiency, a bacterial origin of replication, a sequence encoding an affinity tag, and a protease cleavage site that can remove the tag), and an antibiotic resistance gene (e.g., ampicillin or kanamycin). The expression vector can be replicated in a bacterial host (e.g., DH10B and DH5-α strains), purified, and then used to transform other bacterial strains suitable for recombinant protein expression (e.g., E. coli BL21, BL21 (DE3), and K-12 strains). After transformation with the expression vector, the bacteria are grown in a culture medium, and antibiotics are usually added to prevent the growth of untransformed cells. Depending on the nature of the promoter, protein expression can then be induced, for example, by adding nutrients or drugs (e.g., lactose or IPTG, where the lac promoter is used), or by changing environmental variables (e.g., temperature or pH) to the culture medium. Then under the condition that is conducive to protein expression, bacterium is maintained in culture medium.After enough time, harvest and purify the protein expressed from vector.Protein with secretion signal can be directly harvested from culture medium.Other proteins retained in bacterial cells can be harvested after concentration and cell lysis, for example, using enzyme digestion cell wall or using physical method (for example ultrasonic treatment).In either case, protein expressed in culture medium or protein released from cell can be purified using methods familiar to those of ordinary skill in the art, for example, filtration, salt precipitation, chromatographic method (for example affinity chromatography, ion exchange chromatography or hydrophobic interaction chromatography) and buffer exchange to remove cell debris, and alternative methods are also possible.Bacterial expression of recombinant proteins is further described in, for example, Langlais, C., Korn, B. (2005). Recombinant Protein Expression in Bacteria. In: Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. Springer, Berlin, Heidelberg. https: / / doi.org / 10.1007 / 3-540-29623-9_4800; Overton TW. Recombinant protein production in bacterial hosts. Drug Discov Today. 2014 May; 19(5):590-601. doi:10.1016 / j.drudis.2013.11.008; Rosano GL and Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front. Microbiol. 5: 172. doi: 10.3389 / fmicb.2014.00172; Rosano, GL, Morales, ES, and Ceccarelli, EA (2019). New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science, 28: 1412-1422. https: / / doi.org / 10.1002 / pro.3668.
[0065] In other embodiments, the IdeS protein variants disclosed herein can be expressed in non-bacterial host cells (e.g., yeast cells, plant cells, insect or mammalian cells) using expression vectors suitable for expressing proteins in such host cells and methods familiar to those of ordinary skill in the art.
[0066] In addition to IdeS variant proteins, the present disclosure provides nucleic acids (e.g., DNA or RNA) comprising nucleotide sequences encoding IdeS protein variants (which may be codon-optimized depending on the type of host cell to be expressed), expression vectors comprising such nucleotide sequences, host cells comprising such expression vectors, methods for producing the IdeS variant proteins of the present disclosure, and methods for purifying proteins after expression. Treatment and prevention methods
[0067] In some embodiments, the disclosure provides a method of administering to a subject in need of preventing or treating a disease or disorder a method of administering an amount of an IdeS variant protein of the disclosure sufficient to prevent or treat the disease or disorder, the disease or disorder being characterized by excessive concentrations of certain IgG antibodies in the blood, plasma or serum of such a subject. In some embodiments, the disease or disorder is treated or prevented by reducing the concentration of IgG antibodies in the blood, plasma or serum of the subject. In some embodiments, the subject is a human subject, and the IgG antibody can be an IgG1, IgG2, IgG3 or IgG4 subclass.
[0068] As used herein, "treat" or "treatment" with respect to a disease or disorder that has manifested in a subject means reducing or arresting its severity or rate of progression, at least partially alleviating at least one symptom or sign associated with such a disease or disorder, or changing the value of a diagnostic assessment or biomarker to a value indicative of a less severe disease state. A therapeutically effective amount of an IdeS variant of the present disclosure is an amount sufficient to treat a disease or disorder in a subject.
[0069] As used herein, "prevent" or "prevention" with respect to a disease or disorder that has not yet manifested in a subject but to which such a subject is believed to be susceptible means preventing or delaying (even temporarily) the onset of a disease process, or the onset of symptoms or signs associated with such a disease or disorder. A prophylactically effective amount of an IdeS variant of the present disclosure is an amount sufficient to prevent a disease or disorder in a subject.
[0070] In some embodiments, the disease or disorder is an autoimmune disorder in which the subject produces IgG antibodies that bind to autoantigens (autoantibodies) expressed (even if unknown) by cells or tissues of the body. Exemplary autoimmune disorders that can be treated using the IdeS variant proteins of the present disclosure include, but are not limited to, Addison's disease, dermatomyositis, Hashimoto's thyroiditis, anti-glomerular basement membrane disease, anti-neutrophil cytoplasmic antibody vasculitis, vasculitis, Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, anti-N-methyl-D-aspartate receptor encephalitis, antiphospholipid antibody syndrome, autoimmune bullous skin diseases, pemphigus, pemphigus foliaceus, endemic pemphigus foliaceus (fogo selvagem), pemphigus vulgaris, autoimmune hemolytic anemia, pernicious anemia, autoimmune hepatitis, autoimmune neutropenia, bullous pemphigoid, celiac disease, chronic urticaria, complete congenital heart block, type 1 diabetes mellitus, acquired epidermolysis bullosa, essential mixed cryoglobulinemia, Goodpasture's syndrome, anti-glomerular basement membrane disease, Graves' disease, Basedow's disease, Guillain-Barré syndrome, acute inflammatory demyelinating polyneuropathy, acute motor axonal neuropathy, acquired hemophilia with FVIII deficiency, idiopathic thrombocytopenic purpura, Lambert-Eaton myasthenic syndrome syndrome, mixed connective tissue disease, myasthenia gravis, dilated cardiomyopathy, myocarditis, neuromyelitis optica, primary biliary cirrhosis, multiple sclerosis, systemic sclerosis, CREST syndrome, rheumatic heart disease, rheumatoid arthritis, reactive arthritis, serum sickness, immune complex type III hypersensitivity reaction, Sjögren's syndrome, systemic lupus erythematosus, lupus nephritis, stiff-person syndrome, vitiligo, scleroderma, transplant rejection, and thrombotic thrombocytopenic purpura; others are possible.
[0071] In some embodiments, antigens against which IgG autoantibodies are generated include, but are not limited to, Ro-RNP complex, La antigen, small nuclear ribonucleoprotein (snRNP), double-stranded DNA, histone, topoisomerase I, centromere, myeloperoxidase, proteinase 3, cardiolipin, citrullinated protein, carbamylated protein, rheumatoid factor, phospholipids, α3 chain of basement membrane collagen (type IV collagen), Rh blood group antigen, I antigen, platelet integrin GpIIB:IIIa, epidermal cadherin, ribosome, pancreatic β cell antigen, myelin basic protein, Carboxypeptidase H, chromogranin A, glutamate decarboxylase, imogen-38, insulin, insulinoma antigen 2 and 2β, islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), proinsulin, phospholipid-β-2 glycoprotein I complex, poly (ADP-ribose) polymerase, Sm antigen of U-1 small nuclear ribonucleoprotein complex, alpha enolase, aquaporin-4, beta arrestin, myelin oligodendrocyte glycoprotein, proteolipid protein, S100β, collagen II, heat shock protein, human cartilage glycoprotein 39, and others are also possible.
[0072] In some embodiments, the disease or disorder is monoclonal gammopathy of undetermined significance (MGUS), in which the paraprotein produced by the abnormal clonal population of plasma cells is IgG.
[0073] In some embodiments, a subject with an autoimmune disease and / or production of autoantibodies or with MGUS is administered a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg of subject body weight or a dose or range between any of the values specifically recited above and a dose or range encompassing any of the values specifically recited above. In some embodiments, treatment of a subject with an autoimmune disease or MGUS with the recited doses of the IdeS protein variants of the present disclosure is effective to treat or prevent the autoimmune disease or MGUS. In some embodiments, treatment of a subject with an autoimmune disease or MGUS with the recited doses of an IdeS protein variant of the present disclosure is effective to reduce the concentration of total IgG in the subject's blood, plasma, or serum by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage decrease or range between any of the values specifically recited above, or a percentage decrease or range encompassing any of the values specifically recited above, or a percentage decrease or range in the subject's blood, plasma, or serum by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the concentration of total IgG in the supernatant is reduced to no more than about 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 grams per liter (g / L) or less or a concentration or range between any of the values specifically recited above and a concentration or range covering any of the values specifically recited above. In some embodiments, treatment of subjects with autoimmune diseases with the IdeS protein variants of the present disclosure at the recited doses effectively inhibits or reduces the effector function (even if unknown) of IgG autoantibodies that bind to autoantigens. In some embodiments, the effector function is mediated by Fc receptors.
[0074] In some embodiments, a second or subsequent dose of the IdeS variant of the present disclosure may be administered to a subject suffering from an autoimmune disease and / or producing autoantibodies or suffering from MGUS, and the additional one or more doses may be the same or different doses as the first dose of the IdeS variant. In some embodiments, the second or subsequent dose may be administered at any suitable interval to maintain an acceptable low level of autoantibodies. The interval may be regular, such as weekly, or every two weeks, or monthly, or every two months, or every 3, 4, 5 or 6 months or some other regular interval. Alternatively, in some embodiments, the subject may be monitored by regularly collecting samples (e.g., blood, plasma, or serum) to determine the concentration or titer of the autoantibodies over time, and administering additional doses of the IdeS protein variant as desired or necessary to maintain the concentration or titer of the autoantibodies within a predetermined range. In some embodiments, the subject is a human subject, and the IgG antibody may be an IgG1, IgG2, IgG3, or IgG4 subclass.
[0075] In some embodiments, the present disclosure provides a method of administering a certain amount of IdeS variant protein of the present disclosure to a human subject sensitized to human leukocyte antigen (HLA) in need of tissue or organ transplantation, the amount being sufficient to reduce or reduce the concentration of anti-HLA IgG antibodies in the blood of such a subject, thereby preventing antibody-mediated rejection after transplantation. In some embodiments, the transplanted organ is a kidney, liver, heart, pancreas, lung or intestine or other organ. In some embodiments, the anti-HLA IgG antibody can be an IgG1, IgG2, IgG3 or IgG4 subclass.
[0076] As is known in the art, HLA sensitization can occur when a person has been exposed to cells from another individual, for example due to a blood transfusion, pregnancy, or a previous organ transplant. After such exposure, the immune system of the sensitized individual recognizes the foreign cells as foreign cells and produces anti-HLA antibodies. When the titer of such circulating antibodies is high enough, they can cause the sensitized host to reject the transplanted tissue or organ through antibody-mediated rejection (AMR) (e.g., antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)) mechanisms.
[0077] Whether the subject is sensitized can be determined by any suitable method. For example, a population reactive antibody (PRA) test can be used to determine whether the subject is sensitized. A calculated PRA score equal to or above a certain threshold means that the subject has a "high immune risk" or "sensitization" and is at risk of AMR if a transplant is performed. Alternatively, a cross-match test can be performed in which a blood sample of a transplant donor is mixed with a blood sample of the subject. A positive cross-match means that the subject has antibodies that react with the donor sample, indicating that the subject has been sensitized and should not be transplanted. In some embodiments, a sensitized subject at risk of AMR exhibits a calculated population reactive antibody test score of at least or about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% or more.
[0078] In some embodiments, a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg of subject body weight or a dose or range between any of the values specifically recited above and a dose or range covering any of the values specifically recited above is administered to a sensitized subject, after which the subject undergoes a tissue or organ transplant. In some embodiments, treatment of a sensitized subject with the recited doses of the IdeS protein variants of the disclosure effectively reduces or eliminates the risk of AMR after tissue or organ transplantation.
[0079] 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 100, 100, 100, 100, 100, 100, 100, 100, 100, 100
[0080] In some embodiments, a second or subsequent dose of an IdeS variant of the present disclosure may be administered to a sensitized subject prior to transplantation, and the additional dose or doses may be the same or different doses as the first dose of the IdeS variant. In some embodiments, the second dose is administered at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 hours or longer after the first dose, or a time period or range between any of the values specifically recited above and a time period or range covering any of the values specifically recited above. In some embodiments, when the subject produces nAbs against IdeS due to previous infection with S. pyogenes, previous administration of IdeS, the presence of particularly high titers of anti-HLA antibodies, and other reasons, it may be desirable to administer more than one dose of an IdeS protein variant. In some embodiments, prior to the second or subsequent administration of an IdeS protein variant of the present disclosure, the subject may be monitored by collecting at least one sample (e.g., blood, plasma, or serum) and testing such sample for concentrations or titers of nAbs or other types of IgG to determine whether additional administration of an IdeS protein variant is desired or necessary.
[0081] In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to convert the subject from a cross-match positive to a cross-match negative using an assay that detects the presence of donor-specific anti-HLA antibodies (DSA) in a blood, plasma, or serum sample from the subject. DSA in such a sample can be quantified using a variety of methods known in the art, such as complement dependent cytotoxicity (CDC), flow cytometry cross-matching (FCXM), and / or multiplex single antigen beads (SAB) assays. Such methods are further described in, e.g., Mulley, WR and J Kanellis, Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist, Nephrology 16:125–133 (2011) (doi: 10.1111 / j.1440-1797.2010.01414.x); Lorant T, et al., Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients, Am J Transplant [American Journal of Transplantation]. 18: 2752–2762 (2018) (DOI: 10.1111 / ajt.14733).
[0082] In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to reduce the concentration of total IgG in the subject's blood, plasma, or serum by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage reduction or range between and encompassing any of the values specifically recited above. In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to reduce the concentration of total IgG in the subject's blood, plasma, or serum by no more than about 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 grams per liter (g / L) or less, or a concentration or range between and encompassing any of the values specifically recited above.
[0083] In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to reduce the concentration of DSA in the blood, plasma, or serum of the subject by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage reduction or range between and encompassing any of the values specifically recited above. The concentration of DSA in a blood, plasma, or serum sample of a subject can be determined using CDC, FCXM, SAB, or any other suitable assay known in the art.
[0084] In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to reduce the calculated population reactive antibody (PRA) assay score of the subject's serum by at least or about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or more, or a percentage reduction or range between and encompassing any of the values specifically recited above. In some embodiments, the dose of the IdeS variant and / or the time period between administration of the IdeS variant and transplantation is sufficient to reduce the calculated population reactive antibody (PRA) assay score of the subject's serum by no more than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% or less, or a concentration or range between and encompassing any of the values specifically recited above. The calculated population reactive antibody (PRA) assay score of the subject's serum can be determined using a complement dependent cytotoxicity (CDC) assay or any other suitable assay known in the art.
[0085] In some embodiments, a second or subsequent dose of the IdeS protein variant of the present disclosure may be administered to a sensitized subject receiving the transplant after transplantation, and the additional one or more doses may be the same or different doses as the first dose of the IdeS variant administered before transplantation. In some embodiments, the second dose is administered at least 12, 24, 36, or 48 hours or 5, 6, 7, 8, 9, 10, 11, 12, or 13 days or 2, 3, or 4 weeks or longer after transplantation, or a time period or range between any of the values specifically listed above and a time period or range covering any of the values specifically listed above. In some embodiments, before the second or subsequent administration of the IdeS protein variant of the present disclosure, the subject may be monitored by collecting at least one sample (e.g., blood, plasma, or serum) and testing the concentration or titer of nAb or other types of IgG of such a sample to determine whether the additional administration of the IdeS protein variant is desired or necessary.
[0086] In some embodiments, the IdeS variants disclosed herein can be used to reduce the concentration of neutralizing IgG antibodies in subjects before gene therapy. In certain methods of gene therapy, they are engineered by modifying the genome of naturally occurring viruses to prevent replication and introduce heterologous genetic information sufficient to express RNA or protein with desired functions in the target cells of the subject. Such modified viruses are referred to as vectors, because their function is to carry new genetic information to the target cells of the patient for the purpose of achieving therapy. Examples of virus types that have been used for engineered gene therapy vectors include adenoviruses, adeno-associated viruses, and lentiviruses (e.g., HIV-1 or HIV-2).
[0087] As known in the art, recombinant AAV vectors are derived from naturally occurring adeno-associated viruses, but are heavily modified to prevent their replication and include heterologous non-viral gene sequences intended to confer therapeutic effects. AAV vectors typically include AAV capsids and modified AAV genomes. Capsids are protein shells containing three viral proteins AAV VP1, VP2 and VP3, responsible for specific binding to target cells, and surrounding and protecting the genome. AAV vectors can use capsids from any naturally occurring serotype or variant, as well as non-naturally occurring capsids that have been derived, modified, engineered or evolved in some way relative to one or more naturally occurring parent capsids to improve their functions. Furthermore, the vector genome is derived from the AAV viral genome, but has been heavily modified. More specifically, the only viral sequence retained is the inverted terminal repeat (ITR), one of which is located at each of the 5' and 3' ends of the single-stranded DNA molecule representing the genome. However, the AAV viral rep and cap genes are completely removed, and they are responsible for encoding four Rep proteins (in AAV2) (involved in key functions such as replication and packaging) and three viral capsid proteins, respectively. In the vector, these genes are replaced by transgenic expression cassettes. The latter sequence is expected to express a transgenic product expected to have some therapeutic effects in the target cells of the transduction. In some vectors, transgenic encoding is missing or defective protein in the patient due to potential gene mutations, and the treatment is expected to provide a functional copy of the gene. For example, transgenic can encode coagulation factor VIII (missing or defective in hemophilia A) or coagulation factor IX (missing or defective in hemophilia B). There may also be transgenics for many other types of protein encoding that can be used in AAV vectors. In other vectors, transgenic can encode RNA or protein that is expected to change the target cell function of the transduction. Examples include regulatory RNA, such as those involved in RNA interference mechanisms, or Cas nucleases expressed for the purpose of achieving gene editing. In order to support the expression of transgenics, the expression cassette is also often included in the target cell with active transcription control sequences, such as promoters that start transgenic transcription and polyadenylation signal sequences that terminate transcription. As is known in the art, the expression cassette may include other functional subsequences, such as enhancers, introns, fillers, miRNA sequences, which are expected to improve desired properties, such as expression levels, tissue specificity of expression, message stability, packaging fidelity, etc. AAV vectors may include other features that are expected to improve or affect function in some desired manner (e.g., using a self-complementary genome). The type of AAV vector used in conjunction with the treatment or prevention methods described herein should not be considered limiting.
[0088] Additional information about AAV vectors can be found, for example, in Pupo, A, et al., AAV vectors: The Rubik's cube of human gene therapy, Mol Ther, 30(12):3515-41 (2022) (doi.org / 10.1016 / j.ymthe.2022.09.015); Li, C and RJ Samulski, Engineering adeno-associated virus vectors for gene therapy, Nat Revs Genetics, 21:255-72 (2020) (doi.org / 10.1038 / s41576-019-0205-4); Wang, D, et al., Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov [Nature Reviews Drug Discovery] 18, 358–378 (2019) (doi.org / 10.1038 / s41573-019-0012-9); Bulcha, JT, et al., Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther [Signal Transduction and Targeted Therapy] 6, 53 (2021) (doi.org / 10.1038 / s41392-021-00487-6).Additional information about lentiviral vectors can be found, for example, in Wolff, JH and Mikkelsen, JG, Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years. J Biomed Sci 29, 79 (2022) (doi.org / 10.1186 / s12929-022-00865-4); Poletti, V and Mavilio, F. Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. Viruses. 2021 Aug 2;13(8):1526 (doi:10.3390 / v13081526).
[0089] One challenge of using modified viruses as gene therapy vectors is that the candidate for gene therapy may have been infected earlier with the same or similar type of virus that formed the vector and generated an antibody response against one or more components of the virus that remain in the vector. Depending on the titer and specificity of the antibodies, their presence in the gene therapy candidate can interfere with the ability of the vector particles to bind to target cells, preventing target cell transduction and expression of the therapeutic transgene carried by the vector. In the best case, this can reduce the effective dose of the vector, requiring a higher dose to compensate, or in the worst case, resulting in the intended gene therapy being ineffective, so that the candidate must be excluded from treatment. For example, many adeno-associated virus (AAV) serotypes and variants naturally infect humans, resulting in some seroconversion and the production of neutralizing antibodies (nAbs) against the capsid proteins used in certain AAV-based vectors. This phenomenon is described, for example, in Rasko, J, et al., Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy, Blood (2022) 140(Suppl 1): 10668–10670 (doi.org / 10.1182 / blood-2022-158305); Kruzik, A, et al., Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors, Mol Ther Meths Clin Devel [Molecular Therapies - Methods and Clinical Development], Vol. 14, P126-133 (2019) (doi.org / 10.1016 / j.omtm.2019.05.014); Weber, T, Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions [Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions], Front Immunol [Immunology Frontier], 12: 658399 (2021) (doi: 10.3389 / fimmu.2021.658399).
[0090] Various strategies have been proposed to mitigate nAb attack on AAV vectors, such as treating gene therapy candidates with drugs that inhibit B cell function, but one particularly promising approach involves administering IgG-degrading enzymes such as IdeS or IdeZ to patients before administering the gene therapy vector. Such methods are described, for example, in the following: Leborgne C, et al., IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. (2020) 26: 1096–101. doi: 10.1038 / s41591-020-0911-7; Elmore ZC, et al., Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight. (2020) 5: e139881. doi: 10.1172 / jci.insight.139881. Due to their superior properties compared to the wild-type IdeS used in earlier experiments, the IdeS variants disclosed herein can be advantageously used to sufficiently reduce the concentration of neutralizing IgG antibodies in the blood of gene therapy candidates so that those who might otherwise be ineligible can be successfully treated with the vector.
[0091] Thus, in some embodiments, the disclosure provides a method of preparing or pre-treating a subject for gene therapy, wherein the subject has a pre-existing neutralizing IgG antibody titer to a component of a gene therapy vector that is sufficiently high to interfere with, reduce or block the ability of the vector to transduce its intended target cells, and if administered to such a subject, by administering to such a subject an amount of an IdeS protein variant of the disclosure, the amount is sufficient to at least temporarily reduce or eliminate the concentration of nAb to a level that no longer interferes with, reduces or blocks vector transduction in the subject. In some embodiments, such treatment is effective to enable the gene therapy vector to be successfully administered to a subject, otherwise the subject would be considered unsuitable for gene therapy due to the presence of an excessively high titer of nAb to a component of the gene therapy vector. In some embodiments, such treatment is effective to reduce the concentration of nAb in the subject's blood, thereby enabling the gene therapy vector to successfully transduce the intended target cells after subsequent administration. In some embodiments, the subject has not received gene therapy treatment, meaning that the subject has never received a specific type of gene therapy or been administered a specific type of gene therapy vector before.
[0092] The titer of pre-existing neutralizing antibodies in serum samples from subjects can be determined using a variety of assays known in the art. Typically, such assays are designed to be in the absence of any added sample (defined as 100%), and it is considered that what dilution of serum or other samples containing nAb effectively inhibits 50% of certain physiologically relevant signals generated by the assay. For example, assays have been designed to detect and quantify nAbs for specific capsids of recombinant AAV vectors, where the signal is a certain amount of reporter protein (e.g., luciferase) produced by in vitro transduction cells. The serial dilutions of serum samples are mixed with a predetermined amount of reporter vectors using the capsid in question. After incubation, the mixture is added to cells in a culture known to support vector binding and reporter transgene expression. As expression proceeds, the amount of signal from the reporter gene (e.g., light output from luciferase) indicates transduction efficiency, which is inversely proportional to the amount of nAb in the mixture. From the relationship graph of sample dilution factor and signal intensity, the dilution factor that causes 50% signal inhibition compared to no added serum is defined as nAb titer. Similar assays have been designed that quantify the number of vector particles (as genome copies) bound to target cells in culture after exposure to a diluted serum sample. The dilution factor that prevents 50% of the vector particles from binding to the target cells is then defined as the titer. The assay is further described, for example, in the following: Meliani, A, et al., Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26, 45–53 (2015) (doi.org / 10.1089 / hgtb.2015.037); Guo, P, et al., Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay, Mol Ther Meths Clin Devel 13: 40-46 (2019) (doi.org / 10.1016 / j.omtm.2018.11.007).
[0093] In some embodiments, prior to administration of the gene therapy vector, the subject to be pretreated with the IdeS protein variant of the present disclosure has a neutralizing antibody titer to the vector of at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650 0, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:1500, 1:1600, 1:1700, 1:1800, 1:1900, 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000 or more, or titers or ranges between and encompassing any of the values specifically recited above. In the foregoing, the ratio indicates the serum sample dilution factor calculated to inhibit 50% of the gene therapy vector activity in a suitable assay, such as a transduction efficiency assay using a reporter vector, or a vector and target cell binding assay, or other suitable assay. In addition, in the foregoing, as indicated by the larger value of the second number in the ratio, a greater dilution indicates a higher concentration of nAb in the sample, and therefore a higher titer of such nAb.
[0094] In some embodiments, nAbs are specific for components of recombinant viral vectors (e.g., adenoviral vectors, adeno-associated viral vectors, or lentiviral vectors, or another vector derived from a virus). In some embodiments, nAbs are specific for proteins (e.g., AAV VP1, VP2, or VP3 capsid proteins) comprising the capsids of AAV vectors. In some embodiments, the capsids recognized by nAbs can be from any naturally occurring AAV serotype or variant (non-limiting examples of which include AAV1, AAV2, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVRh74, or AAVRh10 or other) or from any non-naturally occurring modified, engineered, or evolved AAV or AAV derivatives (non-limiting examples of which include those designated as AAV-2i8, Spark100, AAV-Voy801, AAV-DJ, AAV PHP.B, or many others).
[0095] In some embodiments, a subject is prepared or pretreated for gene therapy with a vector, the subject having a pre-existing neutralizing IgG antibody titer against components of the gene therapy vector that is sufficiently high to interfere with, reduce or block the ability of the vector to transduce its intended target cells, by administering to such a subject a dose of an IdeS variant of the disclosure that is effective to reduce the concentration of nAbs in the subject to a level that no longer interferes with, reduces or blocks vector transduction. In some embodiments, the effective dose of the IdeS protein variants disclosed herein is at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg of subject body weight, or a dose or range between any of the values specifically recited above and a dose or range encompassing any of the values specifically recited above. In some embodiments, treatment of a subject previously administered a gene therapy vector with the recited doses of the IdeS protein variants disclosed herein effectively inhibits or reduces the effector function of neutralizing IgG antibodies produced by the subject against components of the gene therapy vector.
[0096] In some embodiments, pre-treatment of a subject with pre-existing nAb titers to a gene therapy vector is effective to reduce the titer of nAbs to the vector in the subject's blood, plasma or serum by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage reduction or range between and encompassing any of the values specifically recited above. In some embodiments, pre-treatment of a subject with a pre-existing nAb titer to a gene therapy vector is effective to reduce the titer of nAb to the vector in the subject's blood, plasma, or serum to no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, 1:0.1 or less, or a titer or range between and encompassing any of the values specifically recited above.
[0097] In some embodiments, the method of preparing or pre-treating a subject with a pre-existing nAb titer for a gene therapy vector includes administering a single dose of the IdeS protein variant of the present disclosure to such a subject. In other embodiments, these methods include administering multiple doses of IdeS variant proteins, such as 2, 3, 4 or more doses of such IdeS variant proteins. Each dose in a plurality of doses may be the same dose or a different dose. The time period between each of several (more than two) doses may be the same time period or a different time period. Exemplary non-limiting time periods between administration of any two doses of IdeS protein variants include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25, 26, 28, 30, 32, 34, 35, 36, 38, 40, 42, 44, 45, 46, 48 hours or longer, or time periods or ranges between and including any of the values specifically recited above. In some embodiments, when the subject has produced nAbs against IdeS due to previous infection with S. pyogenes, previous administration of IdeS, the presence of particularly high titers of antibodies against gene therapy vectors, and other reasons, it may be desirable to administer more than one dose of IdeS protein variants. In some embodiments, prior to a second or subsequent administration of an IdeS protein variant of the present disclosure, the subject will be monitored by collecting at least one sample (e.g., blood, plasma, or serum) and testing such sample for the concentration or titer of nAb or other types of IgG to determine whether additional administration of an IdeS protein variant is desired or necessary.
[0098] In some embodiments, the methods of the present disclosure further comprise a second step of administering such a gene therapy vector to such a subject after pre-treating the subject with a sufficient dose of the IdeS protein variant of the present disclosure to reduce the titer of nAbs against the gene therapy vector. In some embodiments, the time period between administration of the ideS variant (or the last dose thereof if more than one) and administration of the gene therapy vector is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 14, 150, 155, 156, 160, 165, 168 hours, or 8, 9, 10, 11, 12, 13, 14 days or longer, or time periods or ranges between and encompassing any of the values specifically recited above.
[0099] In some embodiments, in the second step of administering the gene therapy vector to the subject, the gene therapy vector can be any suitable gene therapy vector, taking into account the nature and severity of the subject's underlying health condition, such as a disease or disorder diagnosed as suitable for treatment or prevention using a gene therapy vector. It is within the knowledge of ordinary technicians to select which gene therapy vector to administer, and other aspects of successfully administering such treatment to achieve the desired treatment or prevention results are also within the knowledge of ordinary technicians, such as subject selection and the application of any treatment exclusion criteria, the dosage and dosage form of the gene therapy vector, the number and frequency of dosage administration, the route of administration, the management of adverse events or side effects (such as immune responses to the vector), and follow-up (such as monitoring changes in the health status of the subject indicating efficacy or side effects), assessing clinical endpoints, or collecting tissue or fluid samples to detect and measure changes in biomarkers or other steps. In some embodiments, taking into account the subject's underlying health condition, the nature of the disease or disorder, and other considerations familiar to ordinary technicians in the art, the gene therapy vector is a recombinant AAV vector comprising any suitable capsid and transgene expression cassette. In some embodiments, administration of an IdeS protein variant disclosed herein prior to gene therapy effectively reduces the dose of gene therapy vector that would otherwise need to be administered to a subject to achieve a given level of transduction efficiency, level of therapeutic or prophylactic efficacy, or expression of a given level of transgene product.
[0100] In some embodiments, the AAV vector expresses a functional coagulation factor VIII protein for treating hemophilia A, or a functional coagulation factor IX protein for treating hemophilia B, or a miniaturized but functional (at least partial) version of dystrophin for treating Becker muscular dystrophy or pseudohypertrophic muscular dystrophy. It is also possible to use other AAV vectors expressing other types of transgenes to treat or prevent other types of diseases or disorders. In some other embodiments, the gene therapy vector is a different recombinant viral vector, such as adenovirus (e.g., AdV5), lentivirus (e.g., HIV-1, HIV-2), retrovirus, herpes simplex virus (e.g., HSV1, HSV2), alpha virus, flavivirus, and others are also possible.
[0101] In some embodiments, the methods of the present disclosure further include a third step of administering one or more doses of the IdeS protein variant of the present disclosure to the subject to maintain low levels of nAb in the subject after pre-treating the subject with the IdeS protein variant of the present disclosure to reduce the titer of nAb against the gene therapy vector and then administering the gene therapy vector. In some embodiments, after administration of the gene therapy vector, the dose of the IdeS protein variant to be administered is at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45 or 0.50 mg / kg body weight of the subject, or a dose or range between and encompassing any of the values specifically recited above, which dose is effective to maintain low or undetectable levels of nAbs in the subject. In some embodiments, an IdeS protein variant effective to maintain low or undetectable levels of nAb in the subject is administered to the subject at least or about 3, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours, or 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, or 2.5, 3, 3.5, 4 weeks or longer after administration of the gene therapy vector, or for a time period or range between any of the values specifically recited above, and for a time period or range encompassing any of the values specifically recited above.
[0102] In some embodiments, for example, after gene therapy, a subject is treated post-treatment to maintain a low or undetectable level of nAb, including administering a single dose of the IdeS protein variant disclosed herein to such a subject. In other embodiments, these methods include administering multiple doses of IdeS variant proteins, such as 2, 3, 4 or more doses of such IdeS variant proteins. Each dose in a plurality of doses may be the same dose or a different dose. The time period between each of several (more than two) doses may be the same time period or a different time period. Exemplary non-limiting time periods between administration of any two doses of IdeS protein variants include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25, 26, 28, 30, 32, 34, 35, 36, 38, 40, 42, 44, 45, 46, 48 hours or longer time periods, or time periods or ranges between any of the values specifically recited above and time periods or ranges covering any of the values specifically recited above. In some embodiments, prior to the second or subsequent administration of an IdeS protein variant of the present disclosure, the subject may be monitored by collecting at least one sample (e.g., blood, plasma, or serum) and testing such a sample for concentrations or titers of nAbs or other types of IgG to determine whether additional administration of an IdeS protein variant is desired or necessary.
[0103] In other embodiments, the methods disclosed herein allow for the re-application or re-administration of gene therapy vectors to subjects. Sometimes, in some subjects, the first treatment with gene therapy may produce a suboptimal therapeutic effect or a therapeutic effect that is not of ideal duration. There may be different reasons. For example, the transduction efficiency of target cells may not be as high as expected due to the presence of nAbs in the vector components; the cellular immune system gradually eliminates the transduced cells; gene therapy is administered to pediatric subjects, and as the subjects mature, the organ and body size increase, causing the relative amount of therapeutic transgenic products from the vector to gradually decrease, or for some other reasons. In such cases, it may be desirable to re-administer the same or similar type of vector to the subject at least a second time. However, one challenge to successful re-administration comes from the fact that the first administration of a gene therapy vector can stimulate an immune response to one or more of its components, including the production of nAbs (which may prevent the success of the second administration of the gene therapy vector). Due to its demonstrated efficacy in cleaving and inactivating IgG antibodies, in some embodiments, the present disclosure also provides methods of administering IdeS protein variants to a subject previously treated with a gene therapy vector against which the subject produces neutralizing IgG antibodies to reduce or eliminate the titer of such antibodies, thereby allowing a second or subsequent administration of the same type of vector or a different vector, but the different vector still has the antigenic characteristics of the first vector so as to be recognized by at least some of the same nAbs.
[0104] In some embodiments, prior to re-administration of the gene therapy vector, the subject to be treated with the IdeS protein variant of the present disclosure has a neutralizing antibody titer to the vector of at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:6 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, 1:3000, 1:3000, 1:4000, 1:4000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000, 1:5000
[0105] In some embodiments, the gene therapy vector to be re-administered is a recombinant viral vector, such as an adenoviral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector, or another vector derived from a virus. In some embodiments, the gene therapy vector to be re-administered is an AAV vector that uses the same type of capsid as the vector that was initially administered, or a different capsid that is recognized by the same nAb raised against the capsid of the vector that was initially administered.
[0106] In some embodiments, prior to re-administration of a gene therapy vector, the subject has produced a titer of nAbs produced by a previous gene therapy against the gene therapy vector sufficient to interfere with, reduce, or block the ability of the re-administered vector to transduce its intended target cells, and the subject is administered a dose of an IdeS protein variant of the present disclosure that effectively reduces the concentration of nAbs to a level that no longer interferes with, reduces, or blocks vector transduction in the subject. In some embodiments, an effective dose of an IdeS variant of the disclosure is at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of a subject, or a dose or range between and encompassing any of the values specifically recited above.
[0107] In some embodiments, treatment of a subject with an IdeS protein variant of the present disclosure is effective to reduce the titer of nAbs to the vector to be re-administered by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage reduction or range between and encompassing any of the values specifically recited above. In some embodiments, treatment of a subject with an IdeS protein variant of the present disclosure effectively reduces the titer of nAb to the vector to be re-administered to no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, 1:0.1 or lower, or a titer or range between and encompassing any of the values specifically recited above.
[0108] In some embodiments, treating a subject with an IdeS protein variant before re-administering a gene therapy vector includes administering a single dose of an IdeS protein variant to such a subject, while in other embodiments, treatment includes administering multiple doses of an IdeS variant protein, such as 2, 3, 4 or more doses of such an IdeS variant protein. Each dose in the multiple doses may be the same dose or a different dose. The time period between each of several (more than two) doses may be the same time period or a different time period. Exemplary non-limiting time periods between administering any two doses of an IdeS protein variant include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25, 26, 28, 30, 32, 34, 35, 36, 38, 40, 42, 44, 45, 46, 48 hours or longer time periods, or the time period or range between any of the aforementioned specifically listed values and the time period or range covering any of the aforementioned specifically listed values. In some embodiments, prior to a second or subsequent administration of an IdeS protein variant of the present disclosure, the subject can be monitored by collecting at least one sample (e.g., blood, plasma, or serum) and testing such sample for the concentration or titer of nAb or other types of IgG to determine whether additional administration of an IdeS protein variant is desired or necessary.
[0109] In some embodiments, the methods of the present disclosure further include a second step of re-administering the same type of gene therapy vector to such a subject, or administering a different vector (e.g., an AAV vector using a different capsid) that is still recognized by the nAbs produced by the subject against the initially administered gene therapy vector, after administering the IdeS protein variant of the present disclosure to such a subject in an amount sufficient to reduce the titer of nAbs against the gene therapy vector initially administered to the subject. In some embodiments, the time period between administration of an IdeS variant (or the last dose thereof if more than one) and re-administration of the gene therapy vector is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 50, 52, 54, 55, 56, 58, 60, 62, 64, 65, 66, 68, 70, 72, 74, 75, 76, 78, 80, 84, 85, 90, 95, 96, 100, 108, 110, 120, 125, 130, 132, 135, 140, 144, 145, 150, 155, 156, 160, 165, 168 hours, or 8, 9, 10, 11, 12, 13, 14 days or longer, or time periods or ranges between and encompassing any of the values specifically recited above.
[0110] In some embodiments, the time period between the initial administration of the gene therapy vector and the re-administration of the gene therapy vector is at least or about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 years or longer, or 10, 20, 30, 40, 50 years or longer, or a time period or range between and encompassing any of the values specifically recited above. In some embodiments, the gene therapy vector is re-administered to the subject at least a second time, prior to which the subject is treated with an amount of an IdeS protein variant of the present disclosure that effectively reduces the concentration of nAbs against the vector to a level that no longer interferes with, reduces, or blocks vector transduction in the subject.
[0111] After receiving gene therapy, some subjects may produce an immune response to the product of the gene therapy vector (e.g., the product of the therapeutic transgene contained in the vector). Therefore, subjects receiving gene therapy may experience suboptimal or limited duration of treatment effects. To address these challenges, there is further provided a method of administering the IdeS protein variants disclosed herein to subjects who have been treated with a gene therapy vector to treat or prevent antibody responses to products expressed by a gene therapy vector.
[0112] In some embodiments, a subject previously administered a gene therapy vector is administered an IdeS variant of the present disclosure at a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg of subject body weight, or a dose or range between and encompassing any of the values specifically recited above. In some embodiments, treatment with the recited doses of the IdeS protein variants is effective to treat or prevent an antibody response to the product expressed by the gene therapy vector. In some embodiments, treatment of a subject previously administered a gene therapy vector with the recited doses of an IdeS protein variant of the present disclosure is effective to inhibit or reduce the effector function of neutralizing IgG antibodies produced by the subject against the product expressed by the gene therapy vector.
[0113] In some embodiments, treatment of a subject previously administered a gene therapy vector with the recited doses of an IdeS protein variant of the present disclosure is effective to reduce the titer of nAbs against the product expressed by the gene therapy vector in the subject's blood, plasma, or serum by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a percentage reduction or range between any of the foregoing specifically recited values and encompassing the foregoing specifically recited values. The invention further provides a method of reducing the titer of an nAb to a product expressed by a gene therapy vector to no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, 1:0.1 or less, or a titer or range between and encompassing any of the values specifically recited above.
[0114] In some embodiments, a second or subsequent dose of the IdeS variant of the present disclosure may be administered to a subject previously administered a gene therapy vector, and the additional one or more doses may be the same or different doses as the first dose of the IdeS variant. In some embodiments, the second or subsequent dose may be administered at any suitable interval to maintain an acceptable low level of nAb in the subject's blood, plasma or serum for the product expressed by the gene therapy vector. The interval may be regular, such as weekly, or every two weeks, or monthly, or every two months, or every 3, 4, 5 or 6 months or some other regular interval. Alternatively, in some embodiments, the subject may be monitored by: regularly collecting samples (e.g., blood, plasma or serum) to determine the concentration or titer of antibodies against the product expressed by the gene therapy vector over time, and administering additional doses of the IdeS protein variant as desired or necessary to maintain the concentration or titer of nAb within a predetermined range. In some embodiments, the subject is a human subject, and the IgG antibody may be an IgG1, IgG2, IgG3 or IgG4 subclass.
[0115] In some embodiments, the IdeS protein variants disclosed herein can be administered for the purpose of treatment or prevention as described herein in combination with at least a second type of immunosuppressive therapy. In some embodiments, the second type of immunosuppressive therapy can suppress the innate immune system, B cell activity or function, T cell activity or function, or some other attributes or aspects of the immune system, such as complement activity, antigen presentation, or some other aspects of immune function. The second type of immunosuppressive therapy can be non-specific, such as treatment with steroids, or specific, such as treatment with monoclonal antibodies targeting specific cell surface proteins involved in the immune response mechanism, an example of which is rituximab. In some embodiments, the IdeS protein variants disclosed herein are administered to the subject before, substantially simultaneously with, or after the second type of immunosuppressive therapy is administered to the subject. Typically, but not necessarily, before administering the IdeS protein variant, the second type of immunosuppressive therapy will be administered first, wherein such a first immunosuppressive therapy relies on the administration of an immunosuppressant, such as a monoclonal IgG antibody, which itself will be cleaved in the presence of the IdeS protein variant. Illustrative, non-limiting examples of immunosuppressive agents that can be administered in combination with the IdeS protein variants of the present disclosure include corticosteroids (e.g., prednisone), calcineurin inhibitors (e.g., tacrolimus or cyclosporine), IMDH inhibitors (e.g., azathioprine, leflunomide, or mycophenolate mofetil), JAK inhibitors (e.g., tofacitinib), mTOR inhibitors (e.g., sirolimus, everolimus, or rapamycin), or others (e.g., abatacept, adalimumab, anakinra, basiliximab, certolizumab pegol, daclizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, or vedolizumab), and others are possible. Subjects
[0116] The subject to which the IdeS protein variants of the present disclosure can be applied as described herein can be any suitable subject. In certain embodiments, such subjects include, but are not limited to, humans and non-human primates (e.g., gibbons, gorillas, chimpanzees, orangutans or rhesus monkeys) and other mammals or animals (e.g., livestock (e.g., dogs and cats), farm animals (e.g., poultry (e.g., chickens and ducks) or horses, cattle, goats, sheep, pigs) and experimental animals (e.g., mice, rats, rabbits, guinea pigs). Human subjects can be of any age, such as fetuses, newborns, infants, children, adolescents and adults. Pharmaceutical composition
[0117] The present disclosure further provides a pharmaceutical composition comprising an IdeS protein variant disclosed herein and at least one pharmaceutically acceptable excipient, vehicle, carrier or diluent. The formulation of such a composition is within the knowledge of ordinary technicians, taking into account factors such as storage conditions, stability, dosage and dosage form, convenience, route of administration, and other factors familiar to ordinary technicians. Exemplary non-limiting excipients include pH buffers such as TRIS, phosphates or citrates; antioxidants or reducing agents such as ascorbic acid, methionine or histidine; preservatives such as benzalkonium chloride; stabilizers such as PEG, albumin, gelatin or polyvinyl pyrrolidone; monosaccharides, disaccharides or other carbohydrates such as glucose, sucrose, trehalose, mannose or dextran; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; inorganic or organic salts; wetting agents such as glycerol; and surfactants such as Tween, Triton or Pluronic. Exemplary non-limiting diluents include water, isotonic saline, PBS or Ringer's solution. In certain embodiments, the pharmaceutical composition can be provided in a lyophilized form for subsequent reconstitution with a diluent, as an aqueous suspension or solution, as a liposomal formulation, or as a biodegradable polymer system. The pharmaceutical composition can be formulated for instantaneous or sustained release. The pharmaceutical composition of the present disclosure can be packaged in any suitable single or multiple use container or enclosure for long-term storage, distributed to an end user, or conveniently applied to a subject, non-limiting examples including vials and plastic IV bags. Application method
[0118] The present disclosure further provides methods of administering the pharmaceutical composition of the present disclosure to a subject by any suitable route of administration (including systemic, regional and local delivery routes). Non-limiting examples include administering the pharmaceutical composition continuously or in one or more push injections by intravenous injection or infusion. Other examples include delivering a pharmaceutical composition comprising an IdeS protein variant to a subject by, for example, the following routes: parenteral, intradermal, subcutaneous, transdermal, intramuscular, intraarterial, intraperitoneal, intraarticular, intraosseous, intrathecal, intraorbital, intramucosal, intraparenchymal, intrapleural, intrahepatic, via the portal vein or any other suitable route of administration. Reagent test kit
[0119] The disclosure further provides a test kit, which includes packaging materials and one or more components thereof. The test kit may include a label or package insert, which includes a description of the component or the in vitro, in vivo or ex vivo instructions for use of the component. The test kit may contain a collection of such components (e.g., a vial containing a pharmaceutical formulation of the IdeS protein variants disclosed herein, a separate vial containing a diluent, and a tube and a needle for infusion). In certain embodiments, the test kit refers to a physical structure that holds one or more components of the test kit. The packaging material can maintain the component aseptically, and can be made of materials (e.g., paper, corrugated fiber, glass, plastic, foil, ampoule, vial, tube, etc.) that are commonly used for such purposes. The label or insert may include information identifying one or more of the components in various ways; the amount of the dose; the clinical pharmacology of the active ingredient, including the mechanism of action, pharmacokinetics and pharmacodynamics; indications; the potential therapeutic or preventive benefits of the active ingredients, compositions or components of the kit; potential adverse side effects, complications or reactions; manufacturers; manufacturing location and date; batch number; expiration date; and warnings to the subject or clinician about contraindications or drug interactions. The label or insert may include instructions for the clinician or subject to use one or more of the kit components in a method, use, treatment regimen or treatment regimen. The instructions may include the amount of the dose, the frequency or duration of the dose administration, and instructions for practicing any method, use, treatment regimen or prevention or treatment regimen described herein. The label or insert may include "printed matter", such as paper or cardboard, or alone or fixed on a component, kit or packaging material (e.g., box), or attached to an ampoule, tube or vial containing a kit component.
[0120] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention in any way. In fact, various modifications of the present invention, in addition to those shown and described herein, will become apparent to those skilled in the art through the foregoing description and fall within the scope of the appended claims. Examples Example 1: IdeS variant optimization
[0121] This example illustrates the generation and testing of IdeS variants with improved properties compared to wild-type IdeS.
[0122] After multiple rounds of optimization, single and multiple substitution variants were designed based on the published crystal structure of the wild-type IdeS protein (Wenig et al. PNAS [Proceedings of the National Academy of Sciences of the United States of America] November 14, 2004, 101 (50) 17371-76). After expressing and purifying the variants, the proteins were tested to identify proteins with improved thermal stability and / or potency compared to the wild-type. The results of these screens are shown in Table 3, where the position numbers of the substituted amino acids refer to the wild-type IdeS precursor protein (SEQ ID NO: 1), including the naturally occurring secretion signal. The corresponding SEQ ID NOs are listed in Table 1. Among the optimized variant proteins, at least those designated GBT-IdeS-0037, GBT-IdeS-0045 and GBT-IdeS-0085 all exhibited greater thermal stability and potency relative to wild-type IdeS. Variant and control wild-type IdeS (designated GBT-NCC-0005) were expressed with an amino-terminal Met-Gly (MG) instead of the naturally occurring secretion signal and a carboxy-terminal His tag (SEQ ID NO: 85) to facilitate purification. ND = Not Determined. Table 3 Example 2: Stability and potency of certain IdeS variants
[0123] This example illustrates the improved characteristics of certain IdeS variants compared to wild-type IdeS.
[0124] Variant IdeS proteins were generated and evaluated for stability and potency. Enzyme activity to determine potency was quantified using an activity ELISA assay. Stability was quantified by differential scanning calorimetry (DSC) at 37°C in PBS pH 7.2 (20 mM sodium phosphate, 400 mM NaCl; neat, 10 μl injection, samples analyzed in parallel using a 300 x 8 mm YMC-Pack Diol-120) after heat-forced degradation. The results are summarized in Figure 2 The data indicate that the IdeS variants GBT-IdeS-0037, GBT-IdeS-0045 (same substitutions as in PF-07899856), GBT-IdeS-0068, and GBT-IdeS-0085 are more stable than wild-type IdeS (GBT-NCC-0005) at physiological temperature.
[0125] Additional studies were performed to compare the potency and stability of the IdeS variants GBT-IdeS-0045 and GBT-IdeS-0085 compared to GBT-NCC-0005 (similar to wild-type IdeS except that it includes a Met-Gly dipeptide at its N-terminus and a His tag at its C-terminus). Enzyme activity to determine potency was assessed using an activity ELISA assay. Stability was assessed by DSC after heat-forced degradation in PBS pH 7.2 formulation at 37°C for 7 days. The results are summarized in Tables 4 and 5 below. HMMS = High Molecular Mass Species Table 4 Table 5
[0126] Compared to GBT-NCC-0005 (similar to wild-type IdeS), the IdeS protein variants GBT-IdeS-0045 and GBT-IdeS-0085 both cleaved IgG more efficiently, exhibited greater thermal stability, and reduced aggregation tendency (or improved colloidal stability) at physiological temperature in PBS. Example 3: Ig cleavage specificity of certain IdeS variants
[0127] This example illustrates that certain IdeS variants specifically cleave IgG, similar to wild-type IdeS.
[0128] Preparations of purified IgG and IgM proteins were incubated with IdeS variants GBT-IdeS-0045 and GBT-IdeS-0085 and IdeS proteins GBT-NCC-0005 and PF-07826653, which are identical to wild-type IdeS in the region corresponding to the mature protein (both are expressed with an N-terminal Met-Gly dipeptide, and GBT-NCC-0005 additionally includes a C-terminal His tag). After incubation, the reactions were quenched with SDS buffer and loaded onto a denaturing polyacrylamide gel to resolve the protein fragments resulting from the antibody digestion, followed by Coomassie staining using standard methods. The results of the digested IgG proteins are shown in Figure 3AThe control lanes show protein bands corresponding to intact IgG and IdeS alone. Digestion with wild-type IdeS and each IdeS variant converted the single high molecular weight band corresponding to intact IgG into two smaller bands characterized by F(ab′)2 and Fc fragments. These results indicate that, similar to wild-type IdeS, the two IdeS variants tested also efficiently cleave IgG. Similar experiments were performed to test whether wild-type IdeS and IdeS variants have any activity against IgM antibodies, where the results are shown in Figure 3B As expected, wild-type IdeS was unable to digest IgM proteins, and each of the two IdeS variants tested produced similar results. These results suggest that the IdeS variants GBT-IdeS-0045 and GBT-IdeS-0085 have similar specificity to wild-type IdeS in binding and cleaving IgG but not other immunoglobulins (particularly IgM). Example 4: Pharmacodynamic studies of wild type and IdeS variants
[0129] This example illustrates the efficacy of IdeS variants compared to wild-type IdeS in IgG degradation studies in an animal model.
[0130] In the study, the in vivo potency of the IdeS variant PF-07899856 was compared to that of PF-07826653, which is identical to wild-type IdeS in the portion corresponding to the mature protein. The IdeS variant PF-07899856 has the same substitutions relative to wild-type IdeS as the variant GBT-IdeS-0045, but lacks the C-terminal His tag present in the latter. Both PF-07899856 and PF-07826653 were expressed with an amino-terminal Met-Gly dipeptide instead of the native secretion signal peptide, but after expression and purification, the major species of both proteins lacked the N-terminal Met, presumably removed by endogenous aminopeptidases. The amino acid sequence of PF-07899856, originally expressed with Met-Gly, is provided by SEQ ID NO:74, and the amino acid sequence of PF-07826653 is provided by SEQ ID NO:72. After removal of the N-terminal Met, the amino acid sequence of PF-07899856 is provided by SEQ ID NO: 75, and the amino acid sequence of PF-07826653 is provided by SEQ ID NO: 73. Although PF-07826653 differs from mature wild-type IdeS by one or two residues at the amino terminus, for convenience, it is referred to as "wild-type" in the present invention and Example 5. Male New Zealand white rabbits were given a single dose of PF-07899856 (1 mg / kg IV, n=3) or wild-type IdeS (1 mg / kg IV, n=3), and IgG levels were assessed at different time points after dosing.
[0131] The Meso Scale Discovery (MSD) assay platform was used to evaluate intact IgG and scIgG ( Figure 4 ). In the assay, F(ab')2 goat anti-rabbit IgG, which is specific for F(ab')2, was used as a capture reagent, and biotinylated F(ab')2 goat anti-rabbit IgG (Fc fragment specific) was used as a detection agent. Streptavidin ruthenium was used as a detection reagent. The assay detects intact IgG and scIgG, and does not detect F(ab')2 or Fc fragments. For the assay, the standard curve range in buffer using purified rabbit IgG control was 300–0.00508 ng / mL. The upper limit of quantification (ULOQ) in buffer = 100 ng / mL, and the lower limit of quantification (LLOQ) = 0.015 ng / mL. Endogenous QC (EQC) was determined in the quantitative assay and is summarized in Table 6. Table 6 Individual serum lot number EQC Plate concentration (ng / mL) RAB42 high 13.83 RAB30 middle 1.2 RAB35 Low 0.08
[0132] Both wild-type IdeS and PF-07899856 treatment resulted in a decrease in intact IgG, with the mean maximum decrease observed between 6 and 24 hours after dosing ( Figure 5 Animals treated with the IdeS variant PF-07899856 had less intact IgG compared to animals treated with wild-type IdeS ( Figure 5 IgG rebound was observed at 48 hours and 168 hours after administration. The percentage of cleavage efficiency of wild-type IdeS (rabbits 1-3) and IdeS variant PF-07899856 (rabbits 4-6) is summarized in Table 7. Table 7
[0133] These results suggest that the IdeS variant PF-07899856 is more effective than wild-type IdeS in reducing IgG in vivo. Example 5: Pharmacokinetics (PK) of IdeS variants
[0134] This example illustrates the PK of IdeS variants against IgG in an animal model study.
[0135] The PK of IdeS variant PF-07899856 and wild-type IdeS was evaluated using the Meso Scale Discovery LBA assay. Figure 6 ). In this assay, goat anti-IdeS polyclonal antibody was used as capture reagent and ruthenium-labeled goat anti-IdeS polyclonal antibody was used as detection reagent. For this assay, 100% ROQ was 10.0 ng / ml to 1,280 ng / ml. Tables 8 and 9 provide PK data in male New Zealand white rabbits after a single 1 mg / kg IV dose of wild-type IdeS and IdeS variant PF 07899856, respectively. Figure 7 The time course of IdeS protein plasma concentrations following single dose administration is provided graphically. Table 8 Table 9
[0136] These results indicate that the PK parameters of the IdeS variant PF-07899856 and wild-type IdeS are similar.
[0137] Although the disclosed teachings have been described with reference to various applications, methods, kits and compositions, it should be understood that various changes and modifications may be made without departing from the teachings herein and the inventions claimed below. The aforementioned examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings set forth herein. Although the teachings of the present invention have been described according to these exemplary embodiments, it will be readily appreciated by those skilled in the art that many variations and modifications of these exemplary embodiments are possible without excessive experimentation. All such variations and modifications are within the scope of the teachings of the present invention.
[0138] All references cited herein, including patents, patent applications, papers, textbooks, etc., and references cited therein (to the extent that they have not been cited) are hereby incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials (including but not limited to defined terms, term usage, described techniques, etc.) differs from or contradicts this application, this application shall prevail.
[0139] The foregoing description and examples detail certain specific embodiments of the present invention, and describe the best mode desired by the inventors. However, it will be appreciated that no matter how detailed the foregoing appears in text, the present invention can still be practiced in many ways, and the present invention should be interpreted according to the appended claims and any equivalents thereof.
Claims
1. An isolated cysteine protease that specifically cleaves immunoglobulin G (IgG) antibody molecules.
2. The cysteine protease of claim 1, wherein the protease has greater potency or thermostability relative to wild-type IdeS.
3. The cysteine protease of claim 2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. 起始 ℃, 3.2℃, 3.3℃, 3.4℃, 3.5℃, 3.6℃, 3.7℃, 3.8℃, 3.9℃, or 4.0℃ greater than the wild-type IdeS protein.
4. The cysteine protease of claim 2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. 起始 value, which value is at least or about 44.0°C, 44.1°C, 44.2°C, 44.3°C, 44.4°C, 44.5°C, 44.6°C, 44.7°C, 44.8°C, 44.9°C, 45.0°C, 45.1°C, 45.2°C, 45.3°C, 45.4°C, 45.5°C, 45.6°C, 45.7°C, 45.8°C, 45.9°C, 46.0°C, 46.1°C, 46.2°C, 46.3°C, 46.4°C, 46.5°C, 46.6°C, 46.7°C, 46.8°C, 46.9°C ℃, 47.0℃, 47.1℃, 47.2℃, 47.3℃, 47.4℃, 47.5℃, 47.6℃, 47.7℃, 47.8℃, 47.9℃, 48.0℃, 48.1℃, 48.2℃, 48.3℃, 48.4℃, 48.5℃, 48.6℃, 48.7℃, 48.8℃, 48.9℃, 49.0℃, 49.1℃, 49.2℃, 49.3℃, 49.4℃, 49.5℃, 49.6℃, 49.7℃, 49.8℃, 49.9℃ or 50.0℃.
5. The cysteine protease of claim 2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. M℃, 3.2℃, 3.3℃, 3.4℃, 3.5℃, 3.6℃, 3.7℃, 3.8℃, 3.9℃, or 4.0℃ greater than the wild-type IdeS protein.
6. The cysteine protease of claim 2, wherein the cysteine protease has a T as determined using differential scanning calorimetry. M value, which value is at least or about 51.0°C, 51.1°C, 51.2°C, 51.3°C, 51.4°C, 51.5°C, 51.6°C, 51.7°C, 51.8°C, 51.9°C, 52.0°C, 52.1°C, 52.2°C, 52.3°C, 52.4°C, 52.5°C, 52.6°C, 52.7°C, 52.8°C, 52.9°C, 53.0°C, 53.1°C, 53.2°C, 53.3°C, 53.4°C, 53.5°C, 53.6°C, 53.7°C, 53.8°C, 53.9°C ℃, 54.0℃, 54.1℃, 54.2℃, 54.3℃, 54.4℃, 54.5℃, 54.6℃, 54.7℃, 54.8℃, 54.9℃, 55.0℃, 55.1℃, 55.2℃, 55.3℃, 55.4℃, 55.5℃, 55.6℃, 55.7℃, 55.8℃, 55.9℃, 56.0℃, 56.1℃, 56.2℃, 56.3℃, 56.4℃, 56.5℃, 56.6℃, 56.7℃, 56.8℃, 56.9℃ or 57.0℃.
7. The cysteine protease of claim 2, wherein the cysteine protease has an IgG cleavage potency as determined using ELISA and expressed as an IC50 value that is at least or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5 nM less than wild-type IdeS.
8. The cysteine protease of claim 2, wherein the cysteine protease has an IgG cleavage potency as determined using ELISA and expressed as an IC50 value of at most 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8 or 3.7 nM.
9. The cysteine protease of claim 2, wherein the amino acid sequence of the cysteine protease comprises, consists essentially of, or consists of: Amino acid numbers 1-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 2-312 of any one of SEQ ID NOs: 2-71, or amino acid numbers 3-312 of any one of SEQ ID NOs: 3-71.
10. The cysteine protease of claim 9, wherein the amino acid sequence of the cysteine protease comprises, consists essentially of, or consists of: The amino acid sequence of any one of SEQ ID NOs: 72-82.
11. A pharmaceutical composition comprising the cysteine protease according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier.
12. A method of treating a subject in need of treatment or prevention of a disease or disorder characterized by an excess of IgG antibodies, the method comprising administering to the subject an amount of the cysteine protease of claim 10 effective to reduce the concentration of IgG antibodies in the subject's body fluids.
13. The method of claim 12, wherein the body fluid is blood, plasma or serum.
14. The method of claim 12, wherein the cysteine protease acts by degrading, digesting or inactivating the IgG antibody.
15. The method of claim 12, wherein the disease or disorder is an autoimmune disease or disorder, and wherein administering the cysteine protease is effective to treat or prevent the autoimmune disease or disorder.
16. The method of claim 15, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject.
17. The method of claim 15, wherein the treatment is effective to reduce the concentration of total IgG in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
18. The method of claim 15, wherein the treatment effectively reduces the concentration of total IgG in the subject's body fluids to no more than about 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 grams per liter.
19. A method of treating a sensitized subject in need of a tissue or organ transplant, the method comprising administering to the subject an amount of the cysteine protease of claim 10 effective to reduce the concentration of anti-HLA antibodies in the subject's body fluids sufficient to prevent antibody-mediated rejection of the tissue or organ after transplantation.
20. The method of claim 19, wherein the body fluid is blood, plasma or serum.
21. The method of claim 19, wherein the cysteine protease acts by degrading, digesting or inactivating the anti-HLA antibody.
22. The method of claim 19, wherein the organ is kidney, liver, heart, pancreas, lung or intestine.
23. The method of claim 19, wherein the subject exhibits a calculated population reactive antibody assay score of at least or about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60%.
24. The method of claim 19, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject.
25. The method of claim 19, wherein the treatment is effective to reduce the concentration of anti-HLA antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
26. The method of claim 19, wherein the treatment effectively reduces the concentration of total IgG in the subject's body fluids to no more than about 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05 grams per liter.
27. The method of claim 19, wherein the treatment is effective to reduce the calculated population reactive antibody assay score of the subject's serum by at least or about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
28. The method of claim 19, wherein the treatment is effective to reduce the calculated population reactive antibody assay score of the subject's serum to no more than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%.
29. The method of claim 19, wherein the subject subsequently undergoes a tissue or organ transplant and the time period between administration of the cysteine protease and the subsequent transplant is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 hours.
30. A method of treating a subject in need of therapy with a gene therapy vector, the method comprising administering to the subject an amount of the cysteine protease of claim 10 effective to reduce the concentration of IgG antibodies specific for a component of the gene therapy vector in a body fluid of the subject.
31. The method of claim 30, wherein the body fluid is blood, plasma or serum.
32. The method of claim 30, wherein the cysteine protease acts by degrading, digesting or inactivating the IgG antibody.
33. The method of claim 30, wherein the IgG antibody is a neutralizing antibody.
34. The method of claim 30, wherein the gene therapy vector is a recombinant viral vector.
35. The method of claim 32, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector.
36. The method of claim 33, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:1500, 1:1600, 1:1700, 1:1800, 1:1900, 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000.
37. The method of claim 33, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject.
38. The method of claim 33, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.
39. The method of claim 33, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.
1.
40. The method of claim 33, wherein the subject has not been treated with gene therapy.
41. The method of claim 40, wherein the subject is subsequently treated with the gene therapy vector.
42. The method of claim 41, wherein the gene therapy vector is a recombinant viral vector.
43. The method of claim 42, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector.
44. The method of claim 41, wherein the time period between administration of the cysteine protease and subsequent gene therapy is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 , 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 52, 54, 55, 56, 58, 60, 62, 64, 65, 66, 68, 70, 72, 74, 75, 76, 78, 80, 84, 85, 90, 95, 96, 100, 108, 110, 120, 125, 130, 132, 135, 140, 144, 145, 150, 155, 156, 160, 165 or 168 hours, or 8, 9, 10, 11, 12, 13 or 14 days.
45. The method of claim 41, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:1500, 1:1600, 1:1700, 1:1800, 1:1900, 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000.
46. The method of claim 41, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject.
47. The method of claim 41, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.
48. The method of claim 41, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.
1.
49. The method of claim 33, wherein the subject has been previously treated at least once with the same type of gene therapy vector as the subject in need of therapy.
50. The method of claim 49, wherein the subject is subsequently treated with the gene therapy vector.
51. The method of claim 50, wherein the gene therapy vector is a recombinant viral vector.
52. The method of claim 51, wherein the recombinant viral vector is a recombinant adenoviral vector, a recombinant adeno-associated viral vector or a recombinant lentiviral vector.
53. The method of claim 50, wherein the time period between administration of the cysteine protease and subsequent gene therapy is at least or about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 , 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 52, 54, 55, 56, 58, 60, 62, 64, 65, 66, 68, 70, 72, 74, 75, 76, 78, 80, 84, 85, 90, 95, 96, 100, 108, 110, 120, 125, 130, 132, 135, 140, 144, 145, 150, 155, 156, 160, 165 or 168 hours, or 8, 9, 10, 11, 12, 13 or 14 days.
54. The method of claim 50, wherein the titer of neutralizing antibodies is at least or about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:125, 1:150, 1:175, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:1500, 1:1600, 1:1700, 1:1800, 1:1900, 1:2000, 1:2100, 1:2200, 1:2300, 1:2400, 1:2500, 1:2600, 1:2700, 1:2800, 1:2900, or 1:3000.
55. The method of claim 50, wherein the effective amount of the cysteine protease is a dose of at least or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, or 0.50 mg / kg body weight of the subject.
56. The method of claim 50, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids by at least or about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.
57. The method of claim 50, wherein the treatment effectively reduces the titer of neutralizing antibodies in the subject's body fluids to a value of no more than 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2 or 1:0.
1.
58. The method of any one of claims 12 to 57, wherein the subject is a human subject.
59. The method of any one of claims 12 to 58, wherein the cysteine protease is administered parenterally.
60. The method of claim 59, wherein the cysteine protease is administered intravenously or intraarterially.
61. The method of any one of claims 12, 19 or 30, wherein the step of administering the cysteine protease to the subject is repeated at least once.
62. A kit comprising a container having disposed therein a pharmaceutical composition comprising a cysteine protease, and a label having instructions for performing the method of any one of claims 12 to 61.
63. A polynucleotide encoding the cysteine protease of any one of claims 1 to 10.
64. An expression vector comprising the polynucleotide of claim 63.
65. A host cell comprising the expression vector of claim 64.
66. The host cell of claim 65, wherein the host cell is a bacterial host cell.
67. A method for producing a cysteine protease, the method comprising incubating the host cell of claim 66 under conditions sufficient to express the cysteine protease, and purifying the cysteine protease produced thereby.
